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Lysophosphatidic acid (LPA) is a bioactive acid lysophospholipid that regulates a 
wide array of cellular processes such as migration, proliferation, inhibition of apoptosis, 
wound healing, and morphological changes through activation of G-protein coupled 
receptors.  The overall goal of this thesis was to understand the mechanisms by which 
LPA enhances cell survival by inhibiting apoptosis.  The project was divided into three 
studies: 1) to determine the mechanism of LPA-mediated inhibition of p53 in A549 lung 
carcinoma cells, 2) to investigate the regulation of growth plate chondrocytes by LPA, 
and 3) to determine the mechanisms of LPA-mediated effects in the growth plate. 
In the first study, evidence is provided that LPA reduces the cellular abundance of 
the tumor suppressor p53 in A549 lung carcinoma cells, which express endogenous LPA 
receptors.  The LPA effect depends upon increased proteosomal degradation of p53 and it 
results in a corresponding decrease in p53-mediated transcription.  Inhibition of 
phosphatidylinositide 3-kinase (PI3K) protected cells from the LPA-induced reduction of 
p53, which implicates this signaling pathway in the mechanism of LPA-induced loss of 
p53.  LPA partially protected A549 cells from actinomycin D induction of both apoptosis 
and increased p53 abundance.  These results identify p53 as a target of LPA action and 
provide a new dimension for understanding how LPA stimulates cancer cell division, 
protects against apoptosis, and thereby promotes tumor progression. 
In the second study, the role of LPA in resting zone chondrocytes (RC cells) was 
investigated.  RC cells are regulated by 24,25-dihydroxyvitamin D3 [24,25(OH)2D3] via a 
phospholipase D-dependent pathway, suggesting downstream phospholipid metabolites 
 xvi 
are involved.  In this study, we showed that 24R,25(OH)2D3 stimulates rat costochondral 
RC cells to release LPA.  RC cells also expressed LPA receptors 1-5 (LPA1-5) and the 
LPA-responsive intracellular fatty acid receptor peroxisome proliferator-activated 
receptor-gamma (PPAR-γ).  LPA and the LPA1/3-selective agonist OMPT increased 
proliferation and maturation markers.  The anti-apoptotic effects of LPA and 
24R,25(OH)2D3 were inhibited by the LPA1/3-selective antagonist VPC32183(S).  
Furthermore, apoptosis induced by either inorganic phosphate (Pi) or chelerythrine was 
attenuated by LPA.  LPA prevented apoptotic signaling by decreasing the abundance, 
nuclear localization, and transcriptional activity of p53.  LPA treatment also regulated the 
expression of the p53-target genes Bcl-2 and Bax to enhance cell survival.  Collectively, 
these data suggest that LPA promotes differentiation and survival in RC chondrocytes, 
demonstrating a novel physiological function of LPA signaling. 
In the final study, the mechanism of LPA and 24R,25(OH)2D3-mediated 
inhibition of chondrocyte apoptosis was further investigated.  We found that both 
24R,25(OH)2D3 and LPA rescue of Pi-induced caspase-3 activity.  The actions of 
24R,25(OH)2D3  were dependent upon Gαi, LPA1/3, phospholipase D (PLD), 
phospholipase C (PLC), and calcium (Ca++); whereas, those of LPA were dependent on 
Gαi and PI3K signaling and nuclear export.  24R,25(OH)2D3 decreased both p53 
abundance and p53-medaited transcription and inhibited Pi-induced cytochrome c 
translocation. Moreover, LPA induced an increase mdm2 phosphorylation, a negative 
regulator of p53.  Taken together, these data show that 24R,25(OH)2D3 inhibits Pi-
induced apoptosis through Ca++, PLD, and PLC signaling and through 
 xvii 
LPA/LPA1/Gαi/PI3K/mdm2-mediated degradation of p53, resulting in decreased caspase-




BACKGROUND AND SIGNIFICANCE 
1.1 Lysophosphatidic Acid (LPA) and LPA Receptors 
Lysophosphatidic acid (LPA) (1-acyl-2-sn-glycerol-3-phosphate) is a small, 
serum-borne lysophospholipid.  It was first isolated in E. coli and identified as an 
intermediary in glycerol lipid metabolism (Pieringer and Hokin 1962).  Early work 
demonstrated a role for LPA in platelet aggregation, establishing LPA as a biologically 
active lipid (Gerrard, Kindom et al. 1979; Tokumura, Fukuzawa et al. 1981).  Now, LPA 
is recognized as a versatile, bioactive lysophospholipid that elicits broad phenotypic 
effects such wound healing, morphological changes, migration, proliferation, and cell 
survival (Chun 1999; Goetzl, Kong et al. 1999; Fang, Yu et al. 2000; Fukushima, Weiner 
et al. 2000; Inoue, Nagano et al. 2001; Deng, Wang et al. 2003; Zhang, Baker et al. 2004) 
(Table 1.1).  LPA is produced by activated platelets and a number of cancer cells 
(Borges, Davanzo et al. 1998; Eder, Sasagawa et al. 2000) and exerts its effects on cells 
by activating the cell surface G-protein coupled receptors (GPCRs) LPA1/Edg2, 
LPA2/Edg4, LPA3/Edg7, LPA4/GPR23/P2Y9, LPA5/GPR92, and LPA6/P2Y5 (Goetzl 
and An 1999; McIntyre, Pontsler et al. 2003; Noguchi, Ishii et al. 2003; Lee, Rivera et al. 
2006; Yanagida, Masago et al. 2009).  These receptors collectively stimulate the Gαi 
(LPA1,2,3), Gαq (LPA1,2,3,5), Gαs (LPA5), and Gα12/13 (LPA1,2,5) signaling pathways 
(Fukushima, Kimura et al. 1998; Chun 1999; Anliker and Chun 2004; Lee, Rivera et al. 
2006; Lee, Rivera et al. 2007) (Fig. 1.1). 
LPA GPCRs can be divided into two groups: Endothelial Differentiation Gene 
(Edg) family receptors and the P2Y family receptors.  LPA1 (Edg2), LPA2 (Edg4), and 
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LPA3 (Edg7) are members of the Edg family.  Other members of the Edg GPCR family 
(Edg1, 3, 5, 6, and 8) respond to sphingosine 1-phosphate (S1P) (Hla 2001; Takuwa, 
Takuwa et al. 2002).  Edg family LPA receptors share sequence homology with one 
another and contain a conserved intron that codes for transmembrane domain 6 (Takuwa, 
Takuwa et al. 2002; Anliker and Chun 2004).  Additionally, LPA1 and LPA2 contain C-
terminal protein-protein binding motifs that facilitate LPA-mediated actions (Lin and Lai 
2008; Murph, Nguyen et al. 2008).  Of the Edgs, LPA1 is the most abundantly expressed 
LPA receptor and it is found in almost every tissue (An, Bleu et al. 1998; Anliker and 
Chun 2004).  LPA2 and LPA3 are less widely distributed.  LPA2 is expressed primarily 
in the lungs, kidney, and nervous system, whereas LPA3 is found in the heart, brain, 
lungs, and kidneys (Takuwa, Takuwa et al. 2002).  Collectively, the Edg receptors have 
captured the interest of cancer researchers as potential therapeutic targets.  LPA1-3 
receptor antagonists are under investigation for use as chemotherapeutic agents (Chang, 
Kim et al. 2007; Murph and Mills 2007; Ma, Matsumoto et al. 2009). 
As previously stated, LPA also stimulates some P2Y GPCR family members.  
One such P2Y GPCR is LPA4, also know as P2Y9 (Noguchi, Ishii et al. 2003).  LPA4 is 
only ~25% homologous with the Edg LPA receptors, suggesting a different evolutionary 
ancestor.  In comparison to LPA1-3, little is known about the function of LPA4.  
However, recent studies have implicated LPA4 in embryogenesis and morphological 
changes (Yanagida, Ishii et al. 2007; Ohuchi, Hamada et al. 2008).  LPA also stimulates 
LPA5/GPR92 (Lee, Rivera et al. 2006), a GPCR with a sequence more similar to that of 




TABLE 1.1. Activation of LPA Receptors Elicit Broad Phenotypic Effects.   









(Kim, Lee et al. 2005; 







(Ye, Skinner et al. 2008) 
Oocyte maturation --- Female germ-line 
cells 
(Yue, Yokoyama et al. 
2004) 
Blastocyst implantation LPA3 --- (Ye, Hama et al. 2005) 
Stimulation of hair 
growth 
LPA6 Hair follicles (Pasternack, von 
Kugelgen et al. 2008) 







(Aki, Kondo et al. 2008; 
Nochi, Tomura et al. 
2008; Kalari, Zhao et al. 
2009) 
Morphological changes LPA4 Neurons (Yanagida, Ishii et al. 
2007) 
Inhibition of apoptosis Multiple T-cells, cancer 
cells, 
chondrocytes 
(Goetzl, Kong et al. 
1999; Murph, Hurst-
Kennedy et al. 2007; 
Hurst-Kennedy, Boyan 
et al. 2009) 
Angiogenesis, 
Vascularization 
--- Cancer cells (Hu, Tee et al. 2001; 
Lee, Park et al. 2006) 
Stimulation of 
proliferation 
LPA1, LPA3 Cancer cells, 
astrocytes, 
chondrocytes 
(Kim, Lee et al. 2005; 
Billon-Denis, Tanfin et 
al. 2008; Shano, 
Moriyama et al. 2008) 
Tumor formation LPA2 --- (Lin, Wang et al. 2009) 
Cerebral cortical 
development 
LPA1 Cortical neural 
precursors 
(Estivill-Torrus, 




LPA3 Stomach, heart (Ainslie, Shi et al. 2004; 
Sriwai, Zhou et al. 2008) 






(Karagiosis, Chrisler et 
al. 2009; Komachi, 
Tomura et al. 2009) 














FIGURE 1.1. LPA GPCRs couple to many G alpha subunits. The LPA GPCRs, 
LPA1/Edg2, LPA2/Edg4, LPA3/Edg7, LPA4/GPR23, LPA5/ GPR92, and LPA6/P2Y5, 
collectively stimulate the Gαi, Gαq, Gαs, and Gα12/13 signaling pathways.  As a result LPA 
modulates a number of cellular processes such as proliferation, cell survival, migration, 
and morphological changes. 
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understood.  LPA5 has, however, been show to activate platelets (Williams, Khandoga et 
al. 2009).  Recently, a new GPCR has been identified as a potential LPA receptor: 
P2Y5/LPA6 (Pasternack, von Kugelgen et al. 2008; Yanagida, Masago et al. 2009).  This 
receptor shares the most sequence homology with LPA4, the other P2Y family member, 
and induces Rho-mediated motility.    
In addition to G-protein coupled receptors, LPA is a ligand for one intracellular 
receptor: peroxisome proliferator-activated receptor gamma (PPAR-γ), a nuclear, fatty 
acid receptor that binds a number of other lipid mediators (McIntyre, Pontsler et al. 2003; 
Tsukahara, Tsukahara et al. 2006).  LPA-mediated stimulation of PPAR-γ has been 
linked to prevention of endotoxemia-induced organ injury (Murch, Collin et al. 2007) and 
inhibition of adipocyte differentiation (Simon, Daviaud et al. 2005). 
1.2 LPA Metabolism 
LPA is the simplest of the phospholipids consisting of a single fatty acid chain, a 
glycerol backbone, and a phosphate head group (Tokumura 1995).  LPA can be derived 
from a number of precursor sources including lysophosphatidylcholine (LPC), 
phosphatidic acid (PA), and monoacylglycerol (MAG) (Stracke, Krutzsch et al. 1992; 
Aoki, Taira et al. 2002; Umezu-Goto, Kishi et al. 2002; Bektas, Payne et al. 2005) (Fig. 
1.2).  Additionally, LPA is synthesized through at least two distinct mechanisms: 
extracellular metabolism of lysophospholipids and intracellular cleavage of PA (Aoki 
2004). 
In biological fluids such as serum and salvia, LPA is primarily generated via an 
extracellular mechanism.  Moreover, overabundant extracellular LPA synthesis in ascites 
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from ovarian cancer patients has been strongly linked to tumorigenesis (Xu, Fang et al. 
1995; Lee, Swaby et al. 2006; Yu, Murph et al. 2008).  Extracellular LPA production 
begins with the generation of lysophospholipids such as LPC, LPE, and LPS.  These 
lysophospholipids are derived from membrane phospholipids (PC, PE, PS) through the 
actions of membrane and/or secretory phospholipase A1/2 (PLA1/2) (Aoki 2004).  
Additionally, LPC can be produced as a byproduct of lecithin cholesterol acyltransferase 
(LCAT)-mediated cholesterol ester synthesis (Aoki, Taira et al. 2002).  Next, 
lysophospholipid head groups are cleaved by autotaxin (ATX), a multi-subunit ecto-
enzyme also known as lysophospholipase D (lysoPLD) (Stracke, Krutzsch et al. 1992; 
Yuelling and Fuss 2008), to yield LPA.  LPA can be degraded extracellularly as well.  
Lipid phosphate phosphatases (LPPs, LPP1-3) remove the phosphate head group from 
LPA, resulting in the production of monoacylglycerol (MAG) (Brindley and Pilquil 2009; 
Tomsig, Snyder et al. 2009).  This is a reversible process.  MAG can be converted back 
into LPA when phosphorylated by acylglycerol kinase (AGK) (Bektas, Payne et al. 2005; 
Kalari, Zhao et al. 2009). 
The second mechanism by which LPA is produced occurs intracellularly. 
Membrane phospholipids such as PC and PE are substrates for phospholipase D (PLD), 
which catalyzes the conversion of PE/PC to PA (Jenkins and Frohman 2005).  LPA can 
be generated from PA through the actions of PLA1 or PLA2 (Eder, Sasagawa et al. 2000; 
Sonoda, Aoki et al. 2002).  Conversely, LPA can be acylated by lysophospholipid acyl 











FIGURE 1.2 LPA structure and metabolism. (A) LPA consists of a single fatty acyl 
chain, a glycerol backbone, and a phosphate head group.   (B) LPA is derived from at 
least three precursor lipids: lysophosphatidyl choline (LPC), monoacylglycerol (MAG), 
and phosphatidic acid (PA).  Autotaxin/lysophospholipase D mediates the cleavage of 
choline from LPC yielding LPA.  LPA is reversibly converted to MAG through the 
actions of lysophospholipid phosphatases (LPPs) and acyl glycerol kinase (AGK).  
Moreover, phospholipase A1 (PLA1) or phospholipase A2 (PLA2) mediates the 
metabolism of phosphatidic acid (PA) to LPA.  LPA acylation resulting in the 























synthesis of LPA has been identified in osteoblasts (Panupinthu, Zhao et al. 2007; 
Panupinthu, Rogers et al. 2008) and cancer cells (Eder, Sasagawa et al. 2000; Billon-
Denis, Tanfin et al. 2008). 
1.3 The Role of LPA in Physiology and Disease 
1.3.1 Bone and Cartilage 
 Research carried out during the past decade has shown that LPA is a regulator of 
cartilage.   The first of these studies, conducted by Koople et al, demonstrated that LPA 
induces an increase in intracellular calcium in human articular chondrocytes (Koolpe, 
Rodrigo et al. 1998).  This was followed by the observations that LPA stimulates Gαi/o 
and ERK-mediated proliferation in primary rat articular chondrocytes (Kim, Lee et al. 
2005), while it decreases proliferation in T/C-28a2 cells, an immortalized, juvenile 
human articular chondrocyte cell line (Kokenyesi, Tan et al. 2000; Facchini, Borzi et al. 
2005).  Collectively, these studies demonstrate that chondrocytes are LPA-responsive 
cells.  Moreover, the data suggest chondrocyte responses to LPA may vary in different 
species and in different subtypes of chondrocytes.  Recently, a research group has 
identified a single nucleotide polymorphism (SNP) in the LPA1 receptor that is 
associated with the progression of osteoarthritis (Mototani, Iida et al. 2008), a cartilage 
degenerative disease, suggesting that LPA and LPA1 are involved in cartilage-related 
pathogenesis. 
Actions of LPA in bone are better characterized that those in cartilage.  The pre-
osteoblastic cell line MC3T3-E1 (Karagiosis, Chrisler et al. 2009), the immature 
osteoblast cell line MG63 (Gidley, Openshaw et al. 2006), and primary osteoblasts 
(Panupinthu, Rogers et al. 2008) all respond to LPA, resulting in increased maturation.  
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Panupinthu et al has found that LPA-mediated osteoblast maturation occurs through 
stimulation of the P2X7 receptor.  Activation of P2X7 in osteoblasts leads to PLD-
mediated LPA production, which subsequently enhances osteogenesis (Panupinthu, Zhao 
et al. 2007; Panupinthu, Rogers et al. 2008).  Additionally, studies conducted in 
osteoblast cell lines have shown that LPA and the vitamin D metabolite 1,25(OH)2D3 act 
synergistically to promote maturation by increasing alkaline phosphatase activity and 
cytoskeletal rearrangement (Gidley, Openshaw et al. 2006; Mansell, Farrar et al. 2009).  
These studies suggest the existence of a 1,25(OH)2D3, LPA, PLD signaling axis in bone 
formation.  LPA also regulates cell migration and morphological changes in bone cells.  
After injury, LPA stimulates dendrite formation in osteocytes to reestablish osteocyte 
connectivity (Karagiosis and Karin 2007), which mediates the transmission of physical 
signals in bone.  These data indicate a role for LPA in mechanosensation.  Moreover, 
LPA is an osteoblast chemoattractant (Masiello, Fotos et al. 2006).  Together, these data 
support a role for LPA in bone fracture repair.  LPA has been identified as an osteoblast 
mitogen as well, as evidenced by the ability to stimulate DNA synthesis in osteoblasts via 
a Gαi-dependent mechanism (Caverzasio, Palmer et al. 2000; Grey, Banovic et al. 2001).  
Lastly, emerging research indicates that LPA1 may be significant in bone maintenance.  
In osteoblasts, LPA1 is necessary for LPA-mediated induction of IL-6 and IL-8 
expression (Aki, Kondo et al. 2008) and for the induction of chemotaxis by LPA 
(Masiello, Fotos et al. 2006).  Furthermore, the LPA1-null mouse has a smaller skeleton 
relative to its wild-type counterpart (Contos, Ishii et al. 2002).  Finally, LPA1 has been 
shown the mediate metastasis of breast cancer cells to bone (Boucharaba, Serre et al. 
2004).  As a whole, these studies establish LPA as a regulator of chondrocytes, 
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osteoblasts, and osteocytes, implicating LPA signaling in the regulation of skeletal 
development and in cartilage and bone-related pathogenesis. 
1.3.2 LPA, Cancer, and p53 
As previously mentioned, LPA is regulator of cell proliferation, migration, and 
cell survival.  These functions implicate the lipid mediator in cancer progression.   This is 
most notable in ovarian cancer (Ren, Xiao et al. 2006).   LPA is found in high levels in 
ascites fluid as a result of increased ATX (Tokumura, Kume et al. 2007) and PLA1/2 
(Ren, Xiao et al. 2006) activity.  Ovarian cancer cells also express abnormally high levels 
of LPA receptors (Yu, Murph et al. 2008).  The result of the overabundance of LPA and 
LPA receptors is increased vascularization (Sako, Kitayama et al. 2006), motility (Kim, 
Yun et al. 2008), and invasion (Sengupta, Kim et al. 2007) of ovarian tumors.  Recent 
work has shown that many of these LPA-mediated effects in ovarian cancer are 
dependent upon LPA2 signaling (Jeong, Park et al. 2008; Wang, Wen et al. 2008; Hope, 
Wang et al. 2009).  LPA signaling contributes to breast cancer progression as well.  
Overexpression of ATX or any of the Edg family LPA receptors in transgenic mice 
increases the abundance of estrogen positive, aggressive breast cancer tumors (Liu, 
Umezu-Goto et al. 2009).  Furthermore, exogenous LPA increases motility and invasion 
in breast cancer cell lines though stimulation of LPA1 and LPA2 (Stadler, Knyazev et al. 
2006; Chen, Towers et al. 2007).  Lastly, emerging research indicates that LPA is also a 
regulator of prostate cancer.  A recent clinical study revealed that LPA3 expression levels 
are higher in prostate tumors relative to benign prostate tissue (Zeng, Kakehi et al. 2009), 
implicating this receptor in tumorigenesis.  LPA3, along with LPA1 and LPA2, have also 
been shown to be involved in LPA-mediated motility in the prostate cancer cell line PC3 
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(Hasegawa, Murph et al. 2008).  Taken together, these studies strongly suggest that LPA 
is a key stimulatory factory in cancer progression. 
Despite the established role of LPA in cancer progression, little was known about 
the role of LPA signaling in cell cycle regulation in cancer cells or in normal cells prior 
to the publication of Lysophosphatidic Acid Decreases the Nuclear Localization and 
Cellular Abundance of the p53 Tumor Suppressor in A549 Lung Carcinoma Cells 
(Murph, Hurst-Kennedy et al. 2007).  Our data indicate a role for LPA in the regulation 
of the protein p53, a key regulator of the cell cycle that is mutated in over 50% of all 
cancers (Bartek, Iggo et al. 1990).   p53 is a transcription factor with over 50 
transcriptional targets that promote cell cycle arrest, DNA damage repair and apoptosis 
(Pietenpol, Tokino et al. 1994; Miyashita and Reed 1995; Slee, O'Connor et al. 2004).  In 
response to genotoxic stress, p53 is phosphorylated at residue Serine-15 by ataxia 
telangiectasia mutated (ATM) (Zhang, Li et al. 2005), thus blocking a nuclear export site 
resulting in the accumulation of p53 in the nucleus and increased p53-mediated 
transcription (Zhang and Xiong 2001; Inoue, Wu et al. 2005) (Fig. 1.3).  p53 exerts non-
transcriptional effects in the cell as well by directly interacting with the Bcl-2 family 
proteins in the mitochondrial membrane to promote the release of cyotochrome c into the 
cytoplasm resulting in increased caspase activity (Sayan, Sayan et al. 2006; Speidel, 
Helmbold et al. 2006).  Recent studies have demonstrated that p53 regulates the 
transcriptional activity of Runx2, an osteoblast-specific transcription factor (Lengner, 
Steinman et al. 2006).  This study demonstrated that p53 signaling participates in cell 






FIGURE 1.3. P53 Signaling. (A) The DNA damage-sensing molecule ATM 
phosphorylates p53 at residue Serine-15 in response to double-stranded DNA breaks.  
This phosphorylation results in the masking of a nuclear export site and stabilizes p53, 
allowing p53 to modulate the transcription of genes that control DNA damage repair, cell 
cycle arrest, and apoptosis. (B) Gαi stimulates the PI3K-Akt signaling cascade.  The E3-
ubiquitin ligase mdm2 is an Akt phosphorylation target.  Phosphorylated mdm2 
translocates to the nucleus where it can mono- or poly-ubiquitinate p53, resulting in 
nuclear export and degradation of p53.
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genotoxic stress, the E3-ubiquitin ligase, mdm2, itself a p53 target gene, promotes the 
degradation and nuclear export of p53 (Haupt, Maya et al. 1997).  When cellular mdm2 
activity is low, p53 is mono-ubiquitinated promoting nuclear export.  Conversely, when 
mdm2 activity is high, p53 is poly-ubiquitinated by mdm2 resulting in increased 
proteosomal degradation of the p53 protein (Li, Brooks et al. 2003).  Mdm2 is primarily 
localized in the cytoplasm until phosphorylated by Akt.  This phosphorylation event 
induces the translocation of mdm2 to the nucleus where it can ubiquitinate p53 (Zhou, 
Liao et al. 2001).  
1.3.3 Other LPA-Regulated Processes 
1.3.3.1 The Cardiovascular System 
 The first identified biological function of LPA in vertebrates was its ability to 
induce platelet aggregation (Gerrard, Kindom et al. 1979; Tokumura, Fukuzawa et al. 
1981).  Since that time, LPA has been shown to regulate many other processes in the 
cardiovascular system such as angiogenesis/vascularization (Hu, Tee et al. 2001; Lee, 
Park et al. 2006), vascular smooth muscle contraction (Cremers, Flesch et al. 2003), and 
cardiomyocyte hypertrophy after vascular injury (Hilal-Dandan, Means et al. 2004).  
Moreover, excessive LPA signaling contributes to the progression of diseases such as 
atherosclerosis (Siess, Zangl et al. 1999) and hypertension (Tokumura, Fujimoto et al. 
1999).  Collectively, these studies establish LPA as a key regulator of the cardiovascular 
system.  Many of these LPA-mediated effects can be attributed to activation of the Edg 
family LPA receptors (Chen, Chen et al. 2008; Panchatcharam, Miriyala et al. 2008), 
suggesting that receptor-specific modulators could be used as therapeutic agents.  
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Furthermore, others have suggested ATX activity regulators could be used to control 
LPA signaling in the treatment of cardiovascular disease progression (Federico, Pamuklar 
et al. 2008).   
1.3.3.2 Obesity 
 Obesity and obesity-related diseases correlate with the elevated storage of 
triglycerides in adipose tissue (Calabro and Yeh 2007).  Studies suggest that LPA 
signaling may contribute to this phenomenon.  In vitro work has shown that pre-
adipocytes express ATX mRNA, resulting in ATX-mediated LPA production (Gesta, 
Simon et al. 2002; Ferry, Tellier et al. 2003).  This causes autocrine/paracrine LPA 
signaling that promotes adipocyte differentiation. Moreover, genetically obese mice 
express more adipose ATX mRNA than their wild-type counterparts (Ferry, Tellier et al. 
2003).  Additionally, LPA increases glucose uptake in the 3T3-L1 adipocyte cell line 
through LPA1/3 and PI3K-dependent signaling (Yea, Kim et al. 2008).  LPA also lowered 
serum glucose levels in wild type and diabetic mice without altering insulin levels.  These 
data collectively suggest that LPA is a pro-adipogenic factor.  However, in contrast to the 
aforementioned findings, one group has observed that LPA inhibits differentiation of 
adipocytes through LPA1-mediated inhibition of PPARγ (Simon, Daviaud et al. 2005).  
This suggests that LPA signaling in adipose tissue is complex and may elicit different 
effects depending on adipocyte maturation state.  
1.3.3.3 Fertility and Pregnancy 
LPA is involved in both male and female gamete maturation (Yue, Yokoyama et 
al. 2004; Ye, Skinner et al. 2008), indicating that the lipid mediator is an important factor 
in reproduction.  Recent studies in bovine models have shown that LPA is significant in 
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the maintenance of early pregnancy (Woclawek-Potocka, Brzezicka et al. 2009; 
Woclawek-Potocka, Komiyama et al. 2009).  LPA is produced by bovine endometrial 
cells and acts as an autocrine/paracrine factor to increase prostaglandin production, 
resulting in enhanced corpus luteum viability.  Similar observations have been made in 
mice.  LPA3-null mice have smaller litters due to delayed blastocyst implantation (Ye, 
Hama et al. 2005).  This phenotype can be rescued with the administration of 
prostaglandins.   Additionally, Tokumura et al observed altered ATX activity in pregnant 
patients with preeclampsia or pre-term labor (Tokumura, Kume et al. 2009), suggesting 
that LPA acts to sustain pregnancy in the later stages as well.  Collectively, these studies 
suggest that modulation of LPA signaling may be important in the treatment of infertility 
and the prevention of miscarriage and abnormal pregnancy. 
1.4 The Growth Plate and Vitamin D Metabolite Signaling 
1.4.1 Endochondral Ossification and the Growth Plate 
 Endochondral ossification is the mechanism by which embryonic skeletal 
formation and longitudinal bone growth in children and adolescents occurs.  This process 
is mediated by growth plates, specialized regions of developing cartilage located between 
the epiphysis and the metaphysis (Ballock and O'Keefe 2003) (Fig 1.4). The growth plate 
is divided into four zones of maturation: the resting zone, the proliferative zone, the pre-
hypertrophic/hypertrophic zone, and the calcifying cell zone.   The resting zone, also 
know as the reserve zone, serves as a pool of chondrocytes for the remainder of the 
growth plate.  Resting zone chondrocytes express early chondrogenic markers such as 
collagen II and aggrecan (Reichenberger, Aigner et al. 1991; Yamane, Cheng et al. 2007).  








FIGURE1.4. The growth plate.  The growth plate is divided into three zones of 
maturation: the resting zone, the growth zone, and the hypertrophic zone.  The resting 
zone serves as a pool of chondrocytes for the remainder of the growth plate.  These cells 
proliferate, calcify, and undergo terminal differentiation and apoptosis as the growth plate 
matures.  Resting zone chondrocytes respond preferentially to the vitamin D3 metabolite 
24R,25-dihydroxyvitamin D3, resulting in PLD-mediated maturation and matrix 
production. Image taken from Boyan and Schwartz et al with permission (Boyan, 





proliferate, and organize themselves into columns (growth zone).  In the pre-
hypertrophic/hypertrophic zone, chondrocytes increase in size and remodel their 
extracellular matrix (hypertrophy).   They express late chondrocyte markers such as 
cartilage oligomeric matrix protein (COMP), an extracellular calcium binding protein, 
and collagen X (Reichenberger, Aigner et al. 1991; Ekman, Reinholt et al. 1997).  In the 
calcifying cell zone, the hypertrophic chondrocytes deposit calcium phosphate crystals.  
This allows for the resorption of the calcified matrix by chondroclasts, permitting the 
invasion of blood vessels and the formation of new bone (Teixeira, Mansfield et al. 2001; 
Mansfield, Pucci et al. 2003; Zhong, Carney et al. 2008).   
Growth plate maturation is regulated by a number of hormones, cytokines, and 
growth factors.  Among these effectors, vitamin D metabolites are crucial in maintaining 
the tissue (Boyan, Schwartz et al. 1992).  In the absence of vitamin D signaling, the 
extracellular matrix of cartilage is not calcified, resulting in rickets in children (Ballock 
and O'Keefe 2003), a disorder characterized by a softening of the bones, bowed limbs, 
and increased fracture risks.  Recent studies have shown that the prevalence of rickets is 
increasing in the US (Kreiter, Schwartz et al. 2000; DeLucia, Mitnick et al. 2003), 
particularly in exclusively breastfed African American children.  In comparison to normal 
growth plates, rachitic growth plates exhibit a decreased resting zone and increased 
growth and hypertrophic zones (Itakura, Yamasaki et al. 1978).  Moreover, the columns 
in the growth zone are less organized and expression of collagen types II and X is 
decreased (Reginato, Shapiro et al. 1988).  This same growth plate phenotype is observed 
in vitamin D nuclear receptor-null mice (Yagishita, Yamamoto et al. 2001). 
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In addition to mediating long bone growth and skeletal development, 
endochondral ossification also plays a role in bone fracture healing.  Fracture healing is 
divided into three stages (Gerstenfeld, Cullinane et al. 2003).  The first of these is the 
reactive stage, characterized by inflammation, hematoma formation, and the recruitment 
of stem cells to the damage site.   This is followed by the reparative stage, which involves 
the formation of the fracture callus, a cartilaginous region that is structurally similar to 
the growth plate (Sandberg, Aro et al. 1989; Gerstenfeld, Cullinane et al. 2003).  Finally, 
in the remodeling stage, the cartilage is degraded and replaced by bone.  Studies have 
shown that vitamin D metabolite signaling stimulates bone fracture healing (Kato, Seo et 
al. 1998; Fu, Tang et al. 2009).  Due to the similarities between the growth plate and the 
fracture callus, this can most likely be attributed to vitamin D metabolite-mediated 
regulation of the fracture callus. 
1.4.2 Vitamin D Metabolites  
Vitamin D is a steroid hormone that regulates a number of physiological 
processes such as calcium and phosphate transport, bone remodeling, and immune cell 
activity.   As with other steroid hormones such as estrogen and testosterone, vitamin D is 
derived from cholesterol (Glover, Glover et al. 1952).  However, unlike other hormones, 
vitamin D contains four fused rings instead of the typical five (Procsal, Okamura et al. 
1976).  For this reason, vitamin D is referred to as a “seco-steroid” hormone.  Two major 
isoforms of vitamin D exist: vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol) 
(Procsal, Okamura et al. 1976).  The two isoforms are distinguished structurally by the 
presence of a double bond in D2 that is absent in D3.  Furthermore, D2 is primarily 
synthesized in plants whereas animals produce D3.  
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Circulating vitamin D3 in the body is derived from both dietary sources and 
through de novo synthesis.  De novo synthesis occurs when cholesterol-derived 7-
dehydroxycholesterol (pro-vitamin D3) in cell membranes undergoes photolysis in 
response to UVB radiation from the sun.   This results in the conversion of pro-vitamin 
D3 to vitamin D3, also known as cholecalciferol (Glover, Glover et al. 1952).    Dietary 
sources of vitamin D3 include oily fishes, cod liver oil, and fortified dairy items and fruit 
juices (Lamberg-Allardt 2006).  D3 from these foods is absorbed into the circulation via 
the intestines and is transported in chylomicrons.  In the liver, vitamin D3 is hydroxylated 
to form the metabolite 25-hydroxyvitamin D3 (25-OHD3), which is then further 
hydroxylated in the kidneys to form 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and 
24R,25-dihydroxyvitamin D3 [24,25(OH)2D3] (Holick, Schnoes et al. 1972).  
1,25(OH)2D3 exerts its effects through the classical nuclear vitamin D receptor (nVDR) 
(Tsai and Norman 1973) and at least one membrane receptor, protein disulfide isomerase 
family A, member 3 (PDIA3, also known as Erp60/57 and 1,25-MARRS) (Boyan, Wong 
et al. 2007).  Actions of 1,25(OH)2D3 are broad and include calcium and phosphate 
intestinal absorption and maintenance of bone, cartilage, and immune cells (Deeb, Trump 
et al. 2007; St-Arnaud 2008).   
The biological actions of 24,25(OH)2D3  are less understood than those of 
1,25(OH)2D3.  Unlike 1,25(OH)2D3, 24,25(OH)2D3 has little to no binding affinity for 
nVDR (Tanaka, Wichmann et al. 1983).   Moreover, early studies indicated that 
24,25(OH)2D3 functioned solely as a negative regulator of 1,25(OH)2D3, acting to reduce 
1,25(OH)2D3 serum levels when they became too high (Tanaka and DeLuca 1984; 
Brommage and DeLuca 1985).  These contributed to the notion that 24,25(OH)2D3 was a 
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“waste” vitamin D metabolite with no biological function of its own.  This idea was 
challenged primarily through the work of Henry, et al and Norman, et al.  Together, they 
first identified 24,25(OH)2D3 as an inhibitor of parathyroid hormone (PTH) secretion in 
chickens and dogs (Henry, Taylor et al. 1977; Canterbury, Lerman et al. 1978).  This was 
followed by the observations that 24,25(OH)2D3 is necessary for normal chicken egg 
hatching (Henry and Norman 1978; Norman, Leathers et al. 1983) and that it regulated 
calcium and phosphate homeostasis (Boyle, Omdahl et al. 1973; Norman, Henry et al. 
1980).  Collectively, these studies identified 24,25(OH)2D3 as a physiologically relevant 
vitamin D metabolite capable of eliciting cellular responses. 
1.4.3 Rapid Actions of 24R,25-dihydroxyvitamin D3 in the Growth Plate  
Chondrocytes isolated from the resting zone of rat growth plates respond 
preferentially to 24,25(OH)2D3 with increased alkaline phosphatase activity and [S35]-
incorporation, decreased DNA synthesis, and increased matrix metalloproteinase (MMP) 
activity (Maeda, Dean et al. 2001; Schwartz, Ehland et al. 2002).  Similar observations 
have been made in avian growth plate chondrocytes (Wu, Genge et al. 2006).  
24,25(OH)2D3-mediated effects are maintained in mice lacking nVDR (Boyan, Sylvia et 
al. 2003) and are not inhibited by Ab99, a blocking antibody targeted against PDIA3 
(Boyan, Bonewald et al. 2002).  Additionally, the effects of 24,25(OH)2D3 are rapid, 
inducing protein kinase C (PKC) activation in as little as 9 minutes (Helm, Sylvia et al. 
1996).  Taken together, these data indicate that 24,25(OH)2D3 acts through a membrane 
associated receptor (mVDR24,25) that is distinct from the 1,25(OH)2D3-responsive 
membrane receptor(s).  This conclusion is supported by the findings of Kato et al and 
Larsson et al demonstrating the presence of a membrane-associated 24,25(OH)2D3 
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receptor in chicken fracture calluses and cod enterocytes, respectively (Kato, Seo et al. 
1998; Larsson, Nemere et al. 2001). 
The actions of 24,25(OH)2D3 in the resting zone chondrocytes are mediated 
through rapid activation of PKC.  24,25(OH)2D3 increases the abundance of 
diacylglycerol (DAG) (Helm, Sylvia et al. 1996), an activator of many PKC isoforms.  
PKC activation by 24,25(OH)2D3 is maintained in the presence of chemical inhibitors 
targeted against either phosphatidyl choline (PC) or phosphoinositol (PI)-specific 
phospholipase C (PLC) (Schwartz, Sylvia et al. 2001), indicating that the source of DAG 
stimulating PKC activation is not phosphoinositide derived.  Inhibition of tyrosine kinase 
signaling also does not attenuate rapid actions of 24,25(OH)2D3, eliminating tyrosine 
kinases as a cause of PKC activation (Helm, Sylvia et al. 1996).  Instead, activation of 
PKC by 24,25(OH)2D3 is dependent upon DAG derived from phosphatidic acid (PA) 
generated the actions of by phospholipase D (PLD), specifically PLD2 (Schwartz, Sylvia 
et al. 2001; Sylvia, Schwartz et al. 2001).  Another consequence of PLD activation is the 
production of LPA (Luquain, Singh et al. 2003; Aoki 2004).  These findings implicated 
LPA as a second messenger in 24,25(OH)2D3-directed signaling.  We found that 
24,25(OH)2D3 increased the abundance of extracellular LPA and LPA receptor 1 (LPA1) 
mRNA.  Additionally, inhibition of LPA1 and LPA3 attenuated 24,25(OH)2D3-induced 
chondrocyte maturation and cell survival (Hurst-Kennedy, Boyan et al. 2009).  Resting 
zone chondrocytes responded to LPA with increased DNA synthesis, alkaline 
phosphatase activity, and [35S]-incorporation.  Furthermore, LPA protected chondrocytes 
against inorganic phosphate (Pi)-induced apoptosis by activating the phosphoinositol 3-
kinase (PI3K) and murine double minute 2 (mdm2) signaling, resulting in the degradation 
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of p53 and a decrease in p53-mediated transcription.  Interestingly, this is the same 
mechanism by which LPA enhances cell survival in cancer cells (Murph, Hurst-Kennedy 
et al. 2007).  We have also observed that Gβγ-mediated PLC activation also contributes 
to the inhibition of Pi-induced apoptosis by 24,25(OH)2D3 (Hurst-Kennedy, Boyan, et al, 
unpublished data).  The stimulation of the pro-survival actions of LPA by 24,25(OH)2D3 
establishes an anti-apoptotic function for the metabolite.   
A second phospholipid-dependent mechanism also contributes to the rapid actions 
of  24,25(OH)2D3.  Inhibition of phospholipase A2 (PLA2) enhances PKC activation by 
24,25(OH)2D3, whereas PLA2 activating protein (PLAA) decreases this (Boyan, Jennings 
et al. 2004).  This is in contrast to 1,25(OH)2D3, which elicits its rapid effects via PLA2-
activation (Schwartz, Graham et al. 2005).  Inhibition of PLA2 by 24,25(OH)2D3 results 
in a rapid decrease in arachidonic acid (AA) abundance and cyclooxygenase-1 (COX-1) 
activity (Boyan, Sylvia et al. 1998; Schwartz, Sylvia et al. 2000).  Following the initial 
decrease in PLA2, 24R,25(OH)2D3 upregulates arachidonic acid turnover (Schwartz, 
Swain et al. 1990; Swain, Schwartz et al. 1992), altering fluidity of the plasma 
membrane(Swain, Schwartz et al. 1993), and increasing the production of prostaglandins 
E1 and E2 (PGE1, PGE2) to induce protein kinase A (PKA) activity (Schwartz, Sylvia et 
al. 1999).  Inhibition of PKA mitigated 24,25(OH)2D3-induced rapid signaling and 
chondrocyte maturation, demonstrating the importance of this signaling pathway (Helm, 
Sylvia et al. 1996; Schwartz, Sylvia et al. 1999).  Together, activated PKC and PKA 
promote MEK and ERK1/2 signaling (Schwartz, Ehland et al. 2002) in response 
24,25(OH)2D3 to induce changes in gene transcription to promote chondrocyte 











FIGURE 1.5. Actions of 24R,25-dihydroxyvitamin D3 in growth plate resting zone 
chondrocytes. 24,25(OH)2D3 stimulates phospholipase D (PLD), resulting in 
diacylglycerol (DAG)-mediated protein kinase C (PKC) activation.  Additionally, 
24,25(OH)2D3 rapidly negatively regulates PLA2 activity leading to a reduction in 
arachidonic acid production, an inhibitor of PKC. Together, this results in MAPK 
activation to induce differentiation, proliferation, and matrix synthesis.  Image taken from 
“24,25-(OH)2D3 regulates cartilage and bone via autocrine and endocrine mechanisms”  




24(R),25(OH)2D3 helps to maintain this less mature, calci-
fication incompetent state. PLA2 is down-regulated by
24(R),25(OH)2D3, maintaining matrix vesicle integrity, and
preventing release of enzymes capable of digesting aggre-
can and other inhibitors of calcification into the matrix. In
addition, 24(R),25(OH)2D3 inhibits activity of matrix vesi-
cle proteinases [85]. In GC cells PLA2 is upregulated by
1!,25(OH)2D3, promoting matrix vesicle breakdown, re-
lease of metalloproteinases capable of digesting aggrecan
into the extracellular matrix [85], and exposure of hydroxy-
apatite nucleating sites to the Ca2! and Pi rich extracellular
fluid.
Studies using 24R-hydroxylase knockout mice [86,87]
also support this interpretation. These mice are not able to
produce 24(R),25(OH)2D3 due to the lack of the enzyme
needed to hydroxylate the 24-carbon. They fail to form a
mandible, which is based on formation of Meckel’s carti-
lage, indicating that chondrogenesis requires this vitamin D
metabolite. The fetuses do form long bones, however, so the
need for 24(R),25(OH)2D3 is not absolute. In addition, in
older fetuses, the diaphyseal bone fails to mineralize prop-
erly, indicating that osteoblasts can synthesize osteoid but
cannot deposit mineral, suggesting that 24(R),25(OH)2D3 is
needed for the transition from a less mature osteoblast to a
more mature osteoblast. These mice do produce
1!,25(OH)2D3, so simply transporting Ca
2! into the matrix
is not sufficient. Moreover, these experiments suggest that
local pro uction of 24(R),25(OH)2D3 may be a significant
factor in cell response.
Circulating levels of 24(R),25(OH)2D3 are in the range
of 10"9–10"10 M, however, most of the effects observed in
cell culture are seen at concentrations of 10"7–10"8 M.
Even if one assumes that some of the lipophilic metabolite
adheres to culture dish surfaces, this is a significantly higher
level of hormone than was presumed was being seen by
cells in vivo. Until we actually measured the accumulation
of [3H]24,25(OH)2D3 in epiphyseal cartilage of vitamin
D-replete rats injected with [3H]25-(OH)D3 [39], it was
unclear whether the cell culture experiments from our lab
and others were physiologically relevant. Indeed, levels of
24(R),25(OH)2D3 in the tissue are well within the range of
concentrations that elicit responses from RC cells in vitro,
suggesting that the cells contribute to the local concentra-
tion through extra-renal production.
Our studies have confirmed that RC cells produce both
1!,25(OH)2D3 and 24(R),25(OH)2D3 from 25-(OH)D3 and
that this production is regulated by growth factors and
hormones [88]. Within 1 h of exposure to TGF-"1, the cells
increase production of 1!,25(OH)2D3. TGF-"1 also elicits
an increase in 24(R),25(OH)2D3 production at 24 h, indi-
cating a regulatory loop is involved. The levels of
1!,25(OH)2D3 and 24(R),25(OH)2D3 that are produced in
culture are comparable to the levels of exogenous vitamin D
metabolite needed to observe a physiological response.
Both 1!- and 24R-hydroxylase activities are present in
Fig. 4. Proposed mechanism of action of 24(R),25(OH)2D3. 24(R),25(OH)2D3 binds to its membrane-associated vitamin D receptor, causing an increase in
phospholipase D (PLD) activity, resulting in an increase in diacylglycerol (DAG) production and activation of PKC!. Receptor binding also causes a decrease
in phospholipase A2 (PLA2) activity, resulting in decreased arachidonic acid (AA) release and a decrease in membrane fluidity. The reduction in arachidonic
acid decreases the amount of available substrate for cyclooxygenase-1 (Cox-1), reducing the amount of prostaglandin released. One of these prostaglandins,
PGE2, binds the EP1 receptor, leading to inhibition of PKC. However, since PGE2 is decreased, the amount of inhibition is reduced. Binding to the EP1 and
EP2 receptors also activates protein kinase A (PKA) through production of cAMP. Both pathways, PKC and PKA, result in serine/threonine phosphorylation
of MAP kinase (MAPK), leading to phosphorylation of transcription factors and new gene expression.








PART I. LPA-MEDIATED PROTEOSOMAL DEGRADATION OF 





Lysophosphatidic acid (LPA) is a bioactive lipid found in body fluids that elicits a 
wide range of effects including cell proliferation, migration, morphological changes, 
survival and neointimal formation (Chun 1999; Goetzl, Kong et al. 1999; Fang, Yu et al. 
2000; Fukushima, Weiner et al. 2000; Inoue, Nagano et al. 2001; Deng, Wang et al. 
2003; Zhang, Baker et al. 2004).  LPA is produced in blood by activated platelets to 
facilitate wound healing (Xu, Shen et al. 1998; Lee, Goetzl et al. 2000) and it is also 
produced by a variety of cancer cells (Shen, Belinson et al. 1998; Eder, Sasagawa et al. 
2000).  The diverse actions of LPA are primarily mediated by three seven-
transmembrane, G protein-coupled receptors (GPCRs): LPA1/Edg2, LPA2/Edg4, 
LPA3/Edg7, and possibly also by the metabolic receptor, PPAR-γ (An, Dickens et al. 
1997; An, Bleu et al. 1998; Bandoh, Aoki et al. 1999; McIntyre, Pontsler et al. 2003; 
Noguchi, Ishii et al. 2003).  Recent studies also indicate that the orphan receptors GPR23 
and GPR92 are high affinity LPA receptors (Noguchi, Ishii et al. 2003; Lee, Rivera et al. 
2006).  The LPA-binding GPCRs can collectively activate Gi, Gs, Gq, and G12/13 (Ishii, 
Contos et al. 2000; Noguchi, Ishii et al. 2003; Radeff-Huang, Seasholtz et al. 2004).  The 
resultant effects of LPA are mediated through the activation of downstream signaling 
pathways controlled by these G alpha proteins (Mills and Moolenaar 2003). 
LPA potently stimulates the growth, survival, and motility of a variety of cancer 
cells, some of which can themselves, produce LPA (Mills and Moolenaar 2003).  One 
mechanism for this is through the secretion of autotaxin, a secreted lysophospholipase D, 
that produces LPA from extracellular lysophosphatidylcholine (LPC) (Stracke, Krutzsch 
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et al. 1992; Umezu-Goto, Kishi et al. 2002).  Autotaxin is well known to be involved in 
promoting tumor development, metastasis and angiogenesis and its effects can be 
explained by the extracellular production of LPA. The levels of LPA are high in ascites 
fluid and plasma of patients with ovarian tumors (Fang, Schummer et al. 2002).   LPA 
protects against apoptosis caused by chemotherapeutic agents (Deng, Wang et al. 2003). 
It promotes ovarian tumor development, possibly involving increased cyclin D 
expression (Hu, Albanese et al. 2003).  LPA also increases vascular endothelial growth 
factor production in some cancer cells, which stimulates angiogenesis (Hu, Tee et al. 
2001).  In a colon cancer cell line, LPA increases the synthesis of macrophage migration 
inhibitory factor, which promotes tumor growth (Sun, Nishihira et al. 2003).  LPA levels 
are elevated in the blood of patients with multiple myeloma (Sasagawa, Okita et al. 
1999).  
LPA signaling leads to the activation of both cell-proliferative signaling 
pathways, such as the Ras/Raf/ERK pathway, and cell survival pathways, such as those 
involving phosphatidylinositol-3 kinase (PI3-K) and Akt (Weiner and Chun 1999; 
Brindley 2004).  These effectors are primarily activated via pertussis toxin-sensitive, Gi 
signaling.  Although much is known about the effects of LPA signaling on cancer cell 
growth and motility, relatively little is known about LPA’s effects on cell cycle 
regulators, such as the p53 tumor suppressor.  p53 is a transcription factor that controls 
the expression of genes encoding proteins that regulate apoptosis and cell cycle 
progression (Shen, Real et al. 1983; Raycroft, Schmidt et al. 1991; Symonds, Krall et al. 
1994).  p53 is inactivated in about 50% of all cancers (Hainaut, Soussi et al. 1997).   
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Given the strong mitogenic effects of LPA and the commonly observed loss of 
p53 function in cancer cells, we determined whether LPA signaling affected the function 
of the p53 tumor suppressor. We found that signaling initiated by the LPA receptors 
(LPA1, LPA2, and LPA3) potently inhibited p53-dependent transcription, promoted the 
loss of p53 protein, and protected A549 lung tumor cells from actinomycin D-induced 
apoptosis. These results demonstrate that p53 is a target for the actions of LPA and they 




MATERIALS AND METHODS 
3.1 A549 Cell Culture 
A549 cells were purchased from the American Type Culture Collection 
(Manassas, VA) and grown at 37°C and 5% CO2 in F12K Kaighn’s modification 
medium (Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum, 100 
I.U./ml penicillin, 100 µg/ml streptomycin (HyClone, Logan, UT) and 1.5 g/liter 
NaHCO3 (Biosource International, Camarillo, CA).  
3.2 Reagents 
Lysophosphatidic acid (18:1 LPA; 1-oleoyl-2-hydroxy-sn-glycero-3-phosphate), 
OMPT ((2S)-1-oleoyl-2-o-methyl-glycero-3-phosphothionate), and VPC32183(S) ((S)-
phosphoric acid mono-{2-octadec-9-enoylamino-3-[4-(pyridine-2-ylmethoxy)-phenyl]-
propyl} ester) (Avanti Polar Lipids, Alabaster, AL) were reconstituted in 1% fatty-acid 
free, charcoal-stripped BSA as previously described (Lee, Thangada et al. 1998; 
Pustilnik, Estrella et al. 1999).  Mouse anti-p53 antibody (DO-1) and rabbit anti-p53 (FL-
393), which both detect total p53, were from Santa Cruz Biotechnology Inc (Santa Cruz, 
CA).  Mouse anti-paxillin and mouse anti-Bip antibodies (BD Biosciences, San Jose, CA) 
where used to monitor loading accuracy.  Mouse anti-p21 (556431) and rabbit 
Akt1/protein kinase B (88-100) antibodies were purchased from BD Biosciences and 
Calbiochem (San Diego, CA) respectively. All other reagents were from Sigma or VWR. 
3.3 Transfections 
For all transcriptional reporter gene assays, A549 cells were transiently 
transfected using Lipofectin (Invitrogen) according to the Manufacturer’s guidelines.  
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A549 cells were transfected with 50 µM Akt1 siRNA (Santa Cruz) with DharmaFECT 
(Dharmacon, Lafayette, CO) using antibiotic-free, complete media for gene silencing 
experiments. 
3.4 Immunoblotting 
A549 cells were grown in 150 mm dishes for 24 h before washing with serum-
free medium (SFM) and starving in SFM for 12-16 h prior to the treatments indicated 
above and in figure legends.  Cells were rinsed with ice-cold PBS supplemented with 
phosphatase inhibitors (Active Motif, Carlsbad, CA), detached by scraping and collected 
by centrifugation. Pellets were then solubilized on ice for 30 min with intermittent 
agitation in lysis buffer (10 mM Tris pH 7.4, 100mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1 mM NaF, 20 mM Na4P2O7, 2 mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% 
SDS and 0.5% deoxycholate, (Biosource International) supplemented with 1mM PMSF 
from a 0.3 M stock and protease inhibitor cocktail (1:10 dilution; Sigma).  Protein 
concentration was quantified using a BCA protein assay (Pierce, Rockford, IL).  The 
samples (12-20 µg protein per lane) were then separated by 10% SDS-PAGE and 
transferred to nitrocellulose.  The binding of primary antibodies was detected using 
SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, Il). 
3.5 Indirect Immunofluorescence and Quantification 
Cells were grown on glass cover slips, treated as described, and fixed in 2% 
formaldehyde in PBS.  After blocking non-specific sites with 10% fetal calf serum (PBS-
serum), the cells were permeabilized with 0.02% saponin and incubation with primary 
antibodies.  Cover slips were subsequently rinsed three times with PBS-serum and 
incubated with fluorescently-labeled secondary antibodies.  During the final wash, 
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Hoechst 33342 dye (Molecular Probes, Eugene, OR) was added to label the DNA. 
Samples mounted on glass slides were observed with an Olympus BX40 epifluorescence 
microscope equipped with a 60X plan-apochromat lens and digital photomicrographs 
were obtained with a MagnaFire SP digital camera.  All photographs were obtained using 
the same exposure time.  For quantification of fluorescence intensity, photomicrographs 
of 15-25 cells per time point or experimental treatment were obtained from each 
experiment, which itself was repeated at least three independent times.  The fluorescence 
intensity of the nuclear-localized p53 was measured in each cell using Metamorph 
Imaging Software (Universal Imaging Corporation, Downington, PA). The p53 
fluorescence intensity was normalized by subtracting the background and then dividing 
that value by the fluorescence intensity of DNA labeled with Hoechst dye for each cell.  
Normalized data averages of each photomicrograph from all experiments were combined 
to obtain a grand average throughout.  The data are presented as the mean ± S.E.M.  
Metamorph image analysis showed that cells with bright nuclear p53 had an average  
fluorescence intensity of 0.83 ± 0.06 (n=15 cells); whereas p53NUC-diminished cells had 
an average fluorescence Intensity of 0.38 ± 0.03 (n=15 cells).  Changes in the proportion 
of p53NUC-bright cells were quantified by scoring cells whose nuclear p53 fluorescence 
intensity was judged as being approximately equal to the average fluorescence intensity 
of cells with bright nuclear p53 staining (e.g., ~ 0.8).  One hundred cells per sample were 
randomly selected and scored as exhibiting either bright nuclear p53 staining or as 
diminished nuclear p53 staining, based on relative fluorescence intensity.  The data is 
presented as the mean percentage of p53NUC-bright cells ± S.E.M. 
3.6 Luciferase reporter gene assay 
 31 
Both firefly luciferase and Renilla (pRL-TK) luciferase activities were measured 
36 h post-transfection using a dual luciferase assay kit (Promega, Madison, WI) as 
previously described (Murph, Scaccia et al. 2003; Nguyen, French et al. 2004).  The 
pp53-TA-luc vector contains a p53-response element that is upstream of the luciferase 
reporter (BD Biosciences Clontech).  This plasmid, therefore, provides a measure of the 
transcriptional activity of p53.  The plasmid, pRL-TK, which constitutively expresses 
Renilla luciferase (Promega), was used to normalize for differences in transfection 
efficiency between samples.  The normalized value is defined as the ratio of the p53-
induced firefly luciferase activity to Renilla luciferase.  The data are presented as percent 
of control and were compared to untreated controls.  They are shown as the mean ± 
S.E.M. of triplicate measurements from a representative experiment that was repeated at 
least three times. 
3.7 Cell Viability 
1 x 104 A549 cells were grown in the wells of a 96-well plate for 12 h in complete 
medium and then rinsed three times in SFM before incubating in either SFM, 10 µM 
LPA, 2 µg/ml actinomycin D, or both 10 µM LPA and 2 µg/ml actinomycin D for 24 h.  
After this incubation, 20µl of WST-1 cell viability reagent (Roche) was added to each 
well for 1 h at 37°C.  This assay quantifies cell proliferation and cell viability, based on 
the cleavage of the tetrazolium salt WST-1 to formazan.  The absorbance of each well 
was measured at 450 nm.  The results were normalized to cells grown in SFM alone 
(Control) and are the mean ± S.E.M. of six replicates per condition from a representative 
experiment that was repeated three times with similar results. 
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3.8 Statistical analysis 
The data was analyzed using either a single-factor or two-factor ANOVA 




4.1 LPA decreases p53 expression in A549 cells 
  We first determined how the bioactive lipid, LPA, affected the cellular 
distribution of p53 protein in A549 human lung carcinoma cells since these cells 
proliferate rapidly, express wild-type p53, and contain endogenous LPA receptors (Lu, 
Lin et al. 2002; Hama, Aoki et al. 2004).  p53 was localized by using mouse anti-p53 
antibody (DO-1) and indirect immunofluorescence; the nucleus was visualized by 
staining with Hoechst dye.  In the majority of A549 cells (~70%), p53 was localized in 
the nucleus and, to a lesser extent, in a diffuse cytoplasmic pattern (Fig. 4.1A).  The 
nuclear p53 labeling in these cells was bright; thus, we will refer to these cells as p53NUC-
bright cells.  In contrast, p53 staining was greatly reduced or completely absent from the 
nucleus in approximately 30% of control A549 cells (Fig. 4.1A arrows and Fig.4.2 B, 
SFM); no detectable difference was observed in either the fluorescence intensity or 
distribution of p53 in the cytoplasm of these ‘nuclear p53 diminished’ cells (we will 
henceforth refer to these cells as p53NUC-diminished cells).  We quantified the 
fluorescence intensity of p53 staining in the nucleus of these two populations of cells by 
using MetaMorph image analysis software and normalized it to the fluorescence intensity 
of DNA labeled with Hoechst dye.  In cells exhibiting bright nuclear p53 staining, the 
nuclear fluorescence intensity of p53 was 2.2-fold greater than that observed in cells 
exhibiting reduced p53 staining (p53NUC-bright cells: Fluorescence Intensity = 0.83 ± 
0.06, n=15 cells; p53NUC-diminished cells: Fluorescence Intensity = 0.38 ± 0.03, n=15 




FIGURE 4.1. LPA stimulation reduces the nuclear localization and cellular 
abundance of p53 in A549 cells. A). Localization of endogenous p53 in A549 lung 
carcinoma cells: Endogenous p53 was localized in A549 cells using mouse anti-p53 
antibody and fluorescently-labeled anti-mouse secondary antibodies as described in 
materials and methods; DNA was labeled with Hoescht dye.  Arrows indicate cells that 
displayed reduced nuclear staining of p53, which are referred in the text as p53NUC-
diminished cells. (B,C) Cellular abundance of p53: A549 cells were treated for 6 h 
without LPA (Untreated) or with 10 µM LPA (B).  Alternatively, cells were treated with 
serum-free media, complete media, or complete media supplemented with 10µM LPA for 
6 h (C). Prior to immunoblotting of whole-cell extracts with mouse anti-p53 antibodies or 
mouse anti-paxillin antibodies. The protein band intensities were quantified by 
MetaMorph image analysis, following background subtraction and were normalized to 
the untreated samples as described in materials and methods.  The relative band 




FIGURE 4.2. The LPA-induced reduction of nuclear p53 is inhibited by lactacystin. 
(A) Population effect of LPA on nuclear p53 localization:  Serum-starved A549 cells 
were incubated in the presence or absence of 10 µM LPA for 6 h prior to indirect 
immunofluorescence localization of p53.  Note the marked reduction in the nuclear p53 
staining intensity in LPA-treated cells.  (B) Quantification of p53NUC-bright cells: Serum-
starved A549 cells were stimulated for 6 h with serum-free medium (SFM), 10 µM LPA, 
1 µM OMPT, 2 µg/ml actinomycin D, 20µM lactacystin, or lactacystin and LPA prior to 
the localization of p53 by indirect immunofluorescence of triplicate samples.  One 
hundred cells per sample were randomly selected and scored as either having bright or 
diminished nuclear p53 staining.  The data are presented as the mean percentage of 
p53NUC-bright cells ± S.E.M.  **P< 0.01 compared to control SFM cells. 
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 We next investigated how LPA regulates p53 cellular abundance. Western 
blotting of whole-cell extracts also showed that treatment with 10 µM LPA for 6 h 
reduced the total cellular abundance of p53 by approximately 50% (Fig. 4.1B,C).  In 
contrast, LPA treatment only slightly reduced the cellular abundance of the focal 
adhesion protein paxillin, which was used as a loading control.  Taken together, these 
results indicated that LPA reduced the nuclear localization and total cellular abundance of 
the p53 tumor suppressor in A549 cells. 
In addition to a reduction in the nuclear localization of p53 within a given cell, we 
observed that LPA also decreased the proportion of p53NUC-bright cells (Fig. 4.2A,B).  
We quantified the proportion of p53NUC-bright cells in control and LPA-treated samples 
and found that treatment of A549 cells with a physiological concentration of 10 µM LPA 
for 6 h decreased the proportion of p53NUC-bright cells by almost 35%, relative to control 
cells (Fig. 4.2B, 10 µM LPA).  Treatment of A549 cells with the LPA3-selective agonist, 
(2S)-1-Oleoyl-2-O-Methyl-Glycero-3-Phosphothionate (OMPT) (Hasegawa, Erickson et 
al. 2003), decreased the proportion of p53NUC-bright cells, even more than LPA, by 
approximately 60%, relative to control cells (Fig. 4.2B, 1 µM OMPT).  Genotoxic drugs, 
such as the transcription inhibitor, actinomycin D, enhance the nuclear accumulation of 
p53, which ultimately induces apoptosis in cells (Kirk 1960; Cavalieri and Nemchin 
1968; Kelley, Green et al. 1994).  Treatment of A549 cells with 2 µg/ml actinomycin D 
indeed increased the proportion of p53NUC-bright cells relative to untreated cells (Fig. 
4.2B).   
The rapid degradation of p53 in non-transformed cells is facilitated by ubiquitin- 
and proteosome-mediated degradation, which can occur both in the nucleus and in the 
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cytoplasm (Haupt, Maya et al. 1997; Kubbutat, Jones et al. 1997; Shirangi, Zaika et al. 
2002).  We next tested the effects of inhibiting proteasomal degradation on the proportion 
of p53NUC-bright cells by using the proteasomal inhibitor, lactacystin (20 µM).  
Lactacystin has been demonstrated to inhibit nuclear proteasomal degradation (Joseph, 
Zaika et al. 2003; Rockel, Stuhlmann et al. 2005).  Treatment of cells with lactacystin 
alone also increased the proportion of p53NUC-bright cells relative to untreated cells (Fig. 
4.2B).  More importantly, incubation of A549 cells with both lactacystin (20 µM) and 
LPA (10 µM) prevented the LPA-induced decrease in p53NUC-bright cells (Fig. 4.2B). 
These results indicate that the LPA-induced reduction of p53 in A549 cells is likely 
mediated by ubiquitin- and proteasomal-induced degradation. 
4.2 LPA inhibits p53-stimulated transcription 
 A major function of p53 in cells is to stimulate the transcription of proteins 
involved in DNA repair, apoptosis, or cell-cycle arrest (Hofseth, Hussain et al. 2004).  To 
investigate whether LPA stimulation resulted in the reduction of an endogenous p53-
regulated gene product, we tested the effects of 10 µM LPA on the cellular distribution of 
the cyclin D inhibitor, p21CIP1.  Activated p53 stimulates the transcription of the cyclin 
inhibitor, p21CIP1, which in turn promotes G1 cell-cycle arrest (Zuo, Dean et al. 1998).  In 
untreated cells, both p53 and p21CIP1 were predominantly localized to the nucleus (Fig. 
4.3A).  Approximately 50% of all cells in the population showed p21CIP1 labeling in the 
nucleus (Fig. 4.3B).  Treatment with LPA (10 µM) reduced both p53 and p21CIP1 labeling 
and decreased the proportion of cells showing nuclear p21CIP1 staining to about 25% of 
the total population (Fig. 4.3B).  In contrast, treatment of A549 cells with a genotoxic 
agent, doxorubicin (1 µg/ml), enhanced the nuclear staining of both p53 and p21CIP1 (Fig. 
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4.3A).  Doxorubicin significantly increased the proportion of cells showing p21CIP1 
staining in the nucleus to more than 85% of the population (Fig. 4.3B).  
 Since the expression of p21CIP1 is transcriptionally regulated by p53, we 
hypothesized that the LPA-induced reduction in cellular p21CIP1 was caused by a 
reduction in the transcriptional activity of p53.  To directly test this hypothesis, we used a 
p53-stimulated luciferase reporter gene assay to determine the effects of LPA stimulation 
on p53-dependent transcription (M. Murph, data not shown, (Murph, Hurst-Kennedy et 
al. 2007)).  A549 cells were transiently co-transfected with a plasmid encoding a firefly 
luciferase reporter gene, whose expression is driven by a basal promoter and an upstream 
p53 response element, and with the plasmid pRL-TK, which constitutively expresses 
Renilla luciferase.  The latter plasmid serves to control for variations in transfection 
efficiency. Stimulation of native A549 cells with 10 µM LPA caused a significant 
reduction in p53-dependent transcription of luciferase to approximately 40% of that 
observed in untreated cells.  This indicated that the observed reduction in p53 abundance 
correlated with a decrease in p53-dependent transcription, which likely explains the 
concurrent loss of p21CIP1. 
4.3 The LPA-dependent reduction of p53 abundance is dependent upon PI3K, Akt, 
and nuclear export 
To investigate the LPA signaling pathways that facilitate the reduction of p53, we 
quantified the effects of different pharmacological inhibitors of known LPA signaling 
pathways on the LPA-induced reduction in the proportion of p53NUC-bright cells.  
Treatment of these cells with LPA alone (10 µM) decreased the proportion of p53NUC-




FIGURE 4.3.  LPA stimulation decreases the abundance of p21CIP1. (A) Localization 
of p21CIP1: A549 cells were serum starved for 24 h and then stimulated for 6 h with 
serum-free medium, 10 µM LPA, or 1µg/ml doxorubicin.  The cells were then fixed and 
double-labeled for endogenous p53 and p21 by indirect immunofluorescence.  The 
majority of LPA-stimulated cells showed a reduction in the nuclear labeling of p53 and 
p21 relative to untreated cells. (B) The proportion of cells that showed nuclear labeling of 
p21 following LPA (10 µM) or doxorubicin (1 µg/ml) stimulation was quantified by 
evaluation of 100 cells/replicate of triplicate samples.  The data are shown as the mean 







FIGURE 4.4. LPA-dependent reduction of cellular p53 is dependent on PI3Kinase 
and LPA1/3 signaling.  A549 cells were grown on glass cover slips and were serum 
starved for 24 h.  The cells were incubated with SFM, 10 µM LPA, 50 µM LY294002, 10 
µM of VPC 32183(S), 50 µM PD980559, or a combination of LPA with the 
aforementioned reagents for 6 h prior to fixation and indirect immunofluorescence 
localization of p53. Quantification of cells exhibiting bright p53 nuclear staining was 
conducted as previously described in Figure 1B. **P< 0.01 compared to control, LPA-
treated cells. The data shown are from a representative experiment that was repeated 
three times with similar results.   
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incubation of these cells with the LPA1/LPA3-selective antagonist, VPC32183(S), by 
itself increased the proportion of p53NUC-bright cells.  As expected, the antagonist 
completely prevented the LPA-induced reduction of nuclear p53 staining.  Previous 
studies have shown that LPA receptors promote cell survival of cultured Schwann cells 
by activation of the PI3K pathway (Weiner and Chun 1999).  Consistent with this, 
incubation with the PI3K inhibitor, LY294002, also prevented the LPA-induced reduction 
of nuclear p53 labeling in A549 cells.  In contrast, the MEK inhibitor, PD98059, did not 
protect cells from the LPA-induced reduction of nuclear p53 staining.  These results were 
consistently observed over three independent experiments. 
A major function of PI3K in cell survival signaling is to activate the 
serine/threonine protein kinase, Akt (Downward 2004).   We next tested the role of Akt 
in the LPA-induced reduction of cellular p53, by using siRNA to specifically reduce the 
levels of Akt1 (Fig. 4.5A,B).  Immunoblotting of whole cell extracts with anti-p53 
antibodies showed that LPA stimulation of mock siRNA-transfected cells reduced 
cellular p53 levels by 30% relative to mock-transfected and untreated cells (Fig. 4.5B, 
Mock, + LPA).  The p53 abundance in mock-transfected, untreated cells was set to 100% 
and all other p53 samples were normalized to this sample.  LPA did not alter the cellular 
abundance of the cytoskeletal protein, paxillin (loading control), and only slightly 
reduced the cellular abundance of Akt.  When A549 cells were treated with Akt1 siRNA 
oligonucleotides, the cellular levels of Akt were reduced by 30% (Fig. 4.5A, Akt siRNA).  
Although the reduction of cellular Akt1 was modest, we consistently observed a 
reduction in Akt1 levels that ranged from 30% to 50% over multiple independent 














FIGURE 4.5. LPA promotes p53 reduction through activation of Akt1.  A549 cells 
were grown in 150 mm dishes were either mock transfected or transfected with 50 nM 
Akt siRNA. Forty-eight h post-transfection cells were treated with either serum free 
media or 10 µM LPA for six h. (A) p53 was localized by indirect immunofluorescence in 
mock- and Akt1 siRNA-transfected cells after treatment with vehicle or 10 µM LPA.  
The data shown is from a representative experiment that was repeated three times with 
similar results.  (B) Immunoblotting was conducted with mouse anti p53 (DO-1), mouse 
anti-paxillin, and rabbit anti-Akt1. Band intensities were determined by MetaMorph 
analysis. The numbers below the gels indicate the band intensities relative to untreated, 
mock-transfected cells.  The blot is from a representative experiment that was repeated 








transfection protocol, transfection efficiencies are typically less than 100%.  We 
anticipate that the extent of reduction of Akt in individual cells is likely to be greater.  
Nevertheless, the reduction of Akt1 in cells prevented the LPA-induced reduction of 
cellular p53 abundance (Fig. 6B, upper panel, Akt siRNA).  Reduction of Akt1 did not 
alter the abundance of paxillin (Fig. 6B, lower panel, Akt siRNA).  
The E3 ubiquitin ligase murine double minute 2 (mdm2) is a negative regulator of 
p53 and a phosphorylation target of Akt (Milne, Kampanis et al. 2004).  Mono- and poly-
ubiquitination of p53 results in the nuclear export and proteosomal degradation of the p53 
protein (Li, Brooks et al. 2003).  We determined whether LPA-mediated inhibition of p53 
was dependent upon nuclear export by using the nuclear export inhibitor leptomycin B 
(LMB) (Kudo, Wolff et al. 1998).  LPA reduced the abundance of nuclear p53 relative to 
untreated control (Fig. 4.6).  However, in the presence of LMB, nuclear p53 levels were 
similar in both control and LPA-treated samples, indicated LPA-mediated inhibition of 
p53 is dependent upon nuclear export. 
Taken together, these data indicate that stimulation of LPA1/3 initiates reduction 
PI3K/Akt1-mediated nuclear export and degradation of p53. 
4.4 LPA partially protects A549 cells from genotoxic stress-induced cell death 
Several genotoxic drugs, such as the transcription inhibitor, actinomycin D, 
enhance the nuclear accumulation of p53, which ultimately induces apoptosis in cells 
(Kirk ; Cavalieri and Nemchin 1968; Kelley, Green et al. 1994).  To investigate the 
physiological significance of LPA-induced reduction of p53, we examined the effects of 
LPA on actinomycin D-induced cell death in A549 cells.  LPA protects both ovarian 















FIGURE 4.6.  Degradation of p53 by LPA is dependent upon nuclear export.  
Confluent cultures of A549 cells were treated with serum-free media (control), 1µM 
LPA, 1µg/ml doxorubicin, 30ng/ml leptomycin B (LMB), or a combination of the afore 
mentioned treatments for 6 hours.  After the treatment period, whole cell lysates were 
harvested and then fractionated in nuclear (N) and cytoplasmic (C) fractions using the 
Nuclear Fraction Kit (Active Motif). Immunoblotting was conducted using mouse anti 
p53 (DO1) antibody, mouse anti Bip (ER marker), and mouse anti lamin (nuclear 










chemotherapeutic agents (Frankel and Mills 1996; Deng, Balazs et al. 2002).  A549 cells 
were incubated with, or without 10 µM LPA in the presence, or absence of 2 µg/ml 
actinomycin D, 24 h prior to determining cell viability (Murph, Hurst-Kennedy et al. 
2007).  Actinomycin D reduced the percentage of viable cells by 52% compared to 
control cells.  In contrast, co-incubation of actinomycin D and LPA only resulted in a 
25% reduction in viable cells.  Thus, LPA partially protected cells from actinomycin D-
induced cell death. The LPA-induced attenuation of p53 signaling provides an additional 





















In this study, we describe a novel target of LPA-induced cell signaling.  Namely, 
that LPA through stimulation of its receptors reduces the abundance of the p53 tumor 
suppressor, which in turn decreases p53-dependent transcription.  The LPA-dependent 
reduction of p53 is caused by enhanced degradation since inhibition of proteasomal 
action prevented the loss of p53.  The signaling pathway leading from LPA receptors to 
p53 degradation involves PI3K and Akt since decreasing the activity of either of these 
proteins prevented the reduction of p53.  This novel action of LPA contributes to the cell 
survival and growth promoting effects of LPA. It helps to explain how increased LPA 
action promotes tumor progression and protects tumors against chemotherapy. 
p53 is degraded both in the cytoplasm and in the nucleus through a proteosomal 
pathway (Shirangi, Zaika et al. 2002; Kashuba, Mattsson et al. 2003; O'Keefe, Li et al. 
2003), which we now show to be activated by LPA.  We found that LPA stimulation of 
A549 lung carcinoma cells led to a rapid loss of p53 protein from the nucleus of these 
cells and a concurrent decrease in the cellular levels of total p53.  p53 contains several 
nuclear import signals (NLS) as well as multiple nuclear export signals (NES) (Middeler, 
Zerf et al. 1997; Zhang and Xiong 2001; O'Keefe, Li et al. 2003).  In non-tumorigenic 
cells, association of p53 with the E3 ubiquitin ligase, mdm2, promotes ubiquitination and 
nuclear export of p53 with subsequent degradation of the protein by cytoplasmic 
proteasomes (Wu, Bayle et al. 1993; Haupt, Maya et al. 1997; Kubbutat, Jones et al. 
1997).  However, p53 can also be degraded in the nucleus by nuclear proteasomes 
(Shirangi, Zaika et al. 2002; Joseph, Zaika et al. 2003; Rockel, Stuhlmann et al. 2005).  
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Our data demonstrate that LPA stimulation leads to a dose-dependent, LPA-induced 
decrease of nuclear p53. Furthermore, the proteasomal inhibitor, lactacystin, prevented 
the LPA-induced loss of nuclear p53.  Given that lactacystin inhibits both nuclear and 
cytoplasmic degradation (Rockel 2002), the accumulation of p53 in the nucleus in the 
presence of LPA and lactacystin suggests that LPA may also stimulate p53 degradation in 
the nucleus.  
Consistent with the LPA-induced loss of nuclear p53 protein, we observed a 
corresponding decrease in the expression of the endogenous gene target, p21CIP1.  One of 
the consequences of p53 mobilization is to stimulate the transcription of the cyclin 
inhibitor, p21CIP1, which in turn promotes G1 cell-cycle arrest (Zuo, Dean et al. 1998).  
The concurrent loss of p21 suggested that the LPA-induced loss of p53 led to decreased 
p53-dependent transcription.  In support of this hypothesis, we found that LPA signaling, 
either by endogenous or overexpressed LPA receptors inhibited the expression of a p53-
dependent luciferase transcriptional reporter gene.  
It was intriguing that over-expression of LPA receptors alone was sufficient to 
promote the inhibition of p53-dependent transcription.  However, several lines of 
evidence support the specificity of this response.  First and most important, stimulation of 
native, untransfected A549 cells with LPA alone inhibited p53-dependent transcription.  
This demonstrates that ligand stimulation of endogenous LPA receptors is sufficient to 
reduce p53.  Second, treatment of native A549 cells with the LPA3-selective agonist, 
OMPT (Hasegawa, Erickson et al. 2003), also potently reduced nuclear p53 localization.   
Third, treatment of cells with the LPA1/LPA3-selective antagonist, VPC32183(S), 
suppressed the LPA-induced loss of p53 from the nucleus of A549 cells. Finally, we 
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observed that the inhibition of p53-dependent transcription in cells by LPA receptor 
overexpression is prevented by incubation with exogenous phospholipase B, which 
degrades extracellular LPA that is likely generated by secreted autotaxin, and thus 
inhibits LPA signaling (Stracke, Krutzsch et al. 1992; Valet, Pages et al. 1998; Umezu-
Goto, Kishi et al. 2002; Hama, Aoki et al. 2004). Thus, we propose that an autocrine 
mechanism involving a combination of the intracellular production of LPA and the 
conversion of extracellular LPC to LPA by autotaxin is sufficient to partially activate the 
endogenous LPA receptors in A549 cells and the over-expressed receptors in HepG2 
cells. 
What are the LPA signaling pathways that are responsible for the reduction of p53?  
LPA receptors stimulate multiple G protein-mediated signaling pathways (Fukushima, 
Kimura et al. 1998; Ishii, Contos et al. 2000; Anliker and Chun 2004).  Our data indicate 
that PI3K and the protein kinase, Akt, are involved in the LPA-dependent reduction of 
cellular p53.  The PI3K/Akt signaling pathway is important for cell survival of normal 
and tumorigenic cells (Weiner and Chun 1999; Sautin, Crawford et al. 2001; Deng, Wang 
et al. 2003; Peres, Yart et al. 2003).  Akt phosphorylates the E3 ubiquitin ligase, mdm2, 
which enhances both mdm2’s nuclear import and its ubiquitin ligase activity.  Thus, LPA 
stimulation of Akt may lead to increased p53 degradation via enhanced mdm2 activity 
(Fig. 5.1). 
What are the consequences of LPA-induced attenuation of p53?  LPA promotes the 
proliferation of a variety of normal and tumorigenic cells and it stimulates both cell 
proliferative and anti-apoptotic signaling pathways (Mills and Moolenaar 2003).  Studies 












FIGURE 5.1. Proposed mechanism of LPA-mediated inhibition of p53 signaling in 
A459 cells.  The PI3K/Akt signaling cascade is activated in response to ligand stimulation 
of the LPA receptor resulting in increased activity of the E3-ubiquitin ligase, mdm2.  
Activated mdm2 mediates the nuclear export and polyubiquitnation of p53 leading to its 












have focused on the activation of Ras/MAP kinase and Rho GTPase signaling pathways 
as well as stimulation of the serine/threonine kinase, Akt.  However, relatively little is 
known about the effects of LPA signaling on cell cycle regulators such as the p53 tumor 
suppressor.  Our studies highlight a previously unappreciated effect of LPA signaling, 
namely that it decreases p53 concentrations and potently inhibits transcriptional activity 
of p53.  In normal cells, activated p53 promotes G1/S cell cycle arrest and/or apoptosis in 
response to DNA damage (Hofseth, Hussain et al. 2004).  p53 is either mutated, or 
inactivated in 50% of all cancers, which enhances the ability of cancer cells to evade cell 
cycle arrest and apoptosis.  In many tumor cells that contain wild type p53, key down-
stream effectors such as the cyclin kinase inhibitor, p21CIP1, are often mutationally 
inactivated.   
Our results show that LPA receptor-mediated inhibition of p53 activity can enhance 
cancer cell survival by preventing the induction of apoptosis.  We showed that LPA can 
partially protect A549 cells from actinomycin D-induced cell death (Murph, Hurst-
Kennedy et al. 2007).  Actinomycin D inhibits RNA polymerase activity (Wadkins, 
Jares-Erijman et al. 1996), which in turn activates p53 (Ashcroft, Taya et al. 2000).  This 
action could also contribute to the observed effects of LPA in protecting cancer cells 
from cell death caused by chemotherapeutic agents (Frankel and Mills 1996).  The action 
of LPA in increasing cyclin D1 expression (Hu, Albanese et al. 2003) would favor S-
phase entry when LPA also decreases p53 expression.  This would decrease the normal 
effects of p53 in blocking the transition at G1/S and cell cycle progression. This 
unscheduled (by increased cyclin D) and unrestricted (by decreased p53) S-phase entry 
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could lead to the accumulation of DNA damage after many cell generations and 
ultimately favor cell transformation.  
Furthermore, several recent studies have demonstrated the transcription-independent 
induction of apoptosis by cytosolic p53 and p53 localized to mitochondria (Mihara, 
Erster et al. 2003; Chipuk, Kuwana et al. 2004; Erster, Mihara et al. 2004; Leu, Dumont 
et al. 2004).  Cytosolic p53 directly binds and activates the pro-apoptotic protein, Bax, 
which induces the permeabilization of the outer mitochondrial membrane, cytochrome c 
release, and caspase-3 activation (Chipuk, Kuwana et al. 2004).  Alternatively, a fraction 
of the total cellular p53 is translocated to the outer mitochondrial membrane in response 
to apoptotic stimuli (Mihara, Erster et al. 2003; Leu, Dumont et al. 2004).  At the 
mitochondrial membrane, p53 interacts with Bcl-2 family members to promote 
cytochrome c release and caspase-3 activation.  Thus, the LPA-mediated reduction of 
cellular p53 is expected to also diminish the ability of p53 to directly promote apoptosis 
in cancer cells through its interactions with pro-apoptotic and anti-apoptotic Bcl-2 family 
proteins.  Indeed, this may contribute to the observed protection of A549 cells from 
actinomycin D-induced apoptosis by LPA.  Taken together, these actions of LPA on p53 
along with other proliferative signals through the Ras/Raf/ERK pathway can contribute to 
the actions of LPA in promoting tumor growth.  The effect of LPA on p53 expression 
will be particularly critical in many tumor cells that already display decreased p53 levels.   
Our work, therefore, identifies LPA as a physiological agonist that decreases p53 
expression and thus demonstrates a further dimension whereby LPA can both decrease 
apoptosis and increase cell division. The present results provide further insights into the 
role of LPA in promoting cell division versus apoptosis and thereby cell proliferation.  
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The LPA-induced degradation of p53, and its consequent decreased control of cell cycle 
progression and cell death provide a novel dimension for understanding how LPA 










PART II: LPA SIGNALING IN CELL DEATH, MATURATION, AND 





Lysophosphatidic acid (LPA 18:1; 1-oleoyl-2-hydroxy-sn-glycero-3-phosphate) is 
a bioactive lysophospholipid that consists of a single fatty acid chain and is produced by 
activated platelets and cancer cell types (Borges, Davanzo et al. 1998; Eder, Sasagawa et 
al. 2000).  LPA is derived from a number of precursor lipids including phosphatidic acid 
(PA) which is generated by the metabolism of phosphatidyl choline (PC) by 
phospholipase D (PLD) (Aoki 2004).  LPA exerts its effects on cells by activating the cell 
surface G-protein coupled receptors (GPCRs) LPA1/Edg2, LPA2/Edg4, LPA3/Edg7, 
LPA4/GPR23, and LPA5/GPR92 (Chun 1999; Goetzl and An 1999; Noguchi, Ishii et al. 
2003; Lee, Rivera et al. 2006).  These receptors collectively stimulate the Gαi, Gαq, Gαs, 
and Gα12/13 signaling pathways (Fukushima, Kimura et al. 1998; Chun 1999; Anliker and 
Chun 2004; Lee, Rivera et al. 2006; Lee, Rivera et al. 2007).  In addition to G-protein 
coupled receptors, LPA has been shown to activate the nuclear fatty acid receptor 
peroxisome proliferator-activated receptor gamma (PPAR-γ) (McIntyre, Pontsler et al. 
2003).  LPA signaling has been implicated in a wide array of cellular processes including 
wound healing and smooth muscle contraction as well as cell proliferation, survival, and 
migration (van Corven, Groenink et al. 1989; Deng, Balazs et al. 2002; Fang, Schummer 
et al. 2002; Mills and Moolenaar 2003; Hama, Aoki et al. 2004; Ren, Xiao et al. 2006).  
These latter functions support a role for LPA signaling in cancer progression, where LPA 
has been shown to promote tumorigenesis by enhancing adhesion, migration, and 
invasion (Xu, Shen et al. 1998; Fang, Schummer et al. 2002; Ren, Xiao et al. 2006).   
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LPA appears to be involved in regulation of bone and cartilage.  LPA has been 
shown to regulate osteoblasts (Caverzasio, Palmer et al. 2000; Panupinthu, Zhao et al. 
2007) and chondrocytes are also sensitive to the lipid mediator (Kim, Lee et al. 2005)  
These studies suggest that LPA may also be involved in endochondral ossification, a 
process involving the formation of bone upon a cartilage template and the mechanism by 
which long bones in children and adolescents lengthen (Rauch 2005).  This template is 
the result of growth, maturation, and calcification of growth plate cartilage (Ballock and 
O'Keefe 2003), which is regulated in part by the vitamin D metabolites 1,25-dihydroxy 
vitamin D3 [1α,25(OH)2D3] and 24,25-dihydroxy vitamin D3 [24R,25(OH)2D3] (Boyan, 
Schwartz et al. 1992).  LPA acts synergistically with 1α,25(OH)2D3 to promote 
osteoblast differentiation (Gidley, Openshaw et al. 2006), providing evidence of a 
relationship between this metabolite and LPA signaling, but it is not known if there is a 
relationship between LPA and 24R,25(OH)2D3. 
The resting zone of the growth plate provides a reservoir of chondrocytes that will 
eventually undergo terminal differentiation, hypertrophy, and apoptosis as the growth 
plate matures.  The cells in the resting zone are surrounded by a proteoglycan-rich 
extracellular matrix and apoptosis is a relatively infrequent event (Aizawa, Kokubun et 
al. 1997; Erenpreisa and Roach 1999).  These cells respond in particular to the 
24R,25(OH)2D3, resulting in increased cell maturation, matrix synthesis, and cell survival 
(Sylvia, Schwartz et al. 1997; Boyan, Sylvia et al. 2001; Dean, Boyan et al. 2001; 
Schwartz, Ehland et al. 2002).  24R,25(OH)2D3 acts on resting zone chondrocytes via a 
PLD-dependent mechanism (Sylvia, Schwartz et al. 2001) and many 24R,25(OH)2D3-
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mediated effects in resting zone chondrocytes have been shown to be dependent upon 
PLD activation (Boyan, Sylvia et al. 2001).   
These observations implicate LPA as a second messenger during the promotion of 
cell maturation and survival in chondrocytes by 24R,25(OH)2D3.  However, the 
downstream targets by which LPA exerts its effect on growth plate chondrocytes are 
unknown.  One possibility is that LPA acts by modulating the abundance of the tumor-
suppressor p53.  LPA has been shown to promote the degradation of p53 in several 
cancer cell types (Murph, Hurst-Kennedy et al. 2007; Song, Wilkins et al. 2007), 
resulting in increased cell survival.  Reduction of p53 protein abundance is necessary in 
osteoblast maturation (Lengner, Steinman et al. 2006; Tataria, Quarto et al. 2006) 
suggesting that LPA-mediated decreases in p53 may be important in the maintenance of 
cartilage tissue as well. 
The purpose of this study was to investigate the role of LPA signaling in the 
maintenance of the growth plate resting zone.  Specifically, we assessed how LPA 
regulates proliferation, maturation, and apoptotic cell death in growth plate chondrocytes 
using resting zone cells isolated from adult rat costochondral growth plate cartilage as our 
model system.  We found that LPA enhances two markers of chondrocyte maturation: 
alkaline phosphatase enzymatic activity and [35S]-sulfate incorporation.  In addition, LPA 
was found to be a potent stimulator of proliferation.  Lastly, LPA protects resting zone 
chondrocytes from apoptotic cell death by decreasing the abundance of the tumor 
suppressor p53 to alter p53 target gene expression and protein abundance.  Collectively, 
these data suggest that LPA signaling promotes cellular proliferation, maturation and 
survival in resting zone chondrocytes demonstrating a novel physiological function of 
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LPA signaling and providing evidence that LPA produced by the cells in response to 
24R,25(OH)2D3 stimulation may act to mediate its effects on resting zone chondrocytes. 
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CHAPTER 7 
MATERIALS AND METHODS 
7.1 Reagents 
18:1 LPA (1-oleoyl-2-hydroxy-sn-glycero-3-phosphate), OMPT ((2S)-1-oleoyl-2-
O-methyl-glycero-3-phosphothionate), and VPC32183(S) ((S)-phosphoric acid mono-{2-
octadec-9-enoylamino-3-[4-(pyridine-2-ylmethoxy)-phenyl]-propyl} ester) were 
purchased from Avanti Polar Lipids (Alabaster, AL).  All lipid species were reconstituted 
in 1% charcoal-stripped bovine serum albumin (BSA) prior to treatment of cells.  Unless 
otherwise stated, all other reagents were acquired from VWR International (West 
Chester, PA).  
7.2 Cell Culture 
The culture system used in this study has been previously described in detail 
(Boyan, Schwartz et al. 1988).  Chondrocytes were obtained from the resting zone 
(reserve zone) of costochondral cartilage from 125-g male Sprague-Dawley rats and 
cultured in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal bovine 
serum (FBS), 1% antibiotics, and 50 µg/ml ascorbic acid (GIBCO-BRL, Gaithersburg, 
MD).  Primary cells were cultured until fourth passage prior to experimental analysis. 
7.3 LPA Isoforms  
The abundance of LPA isoforms in lysates and media collected from the resting 
zone chondrocyte cultures was determined by liquid chromatography electrospray 
ionization tandem mass spectrometry (LC ESI MS/MS).  Resting zone chondrocytes were 
cultured in T75 flasks and grown until confluence.  Cells were then treated for 30 minutes 
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with starvation media (1% FBS) containing 1% bovine serum albumin (BSA) and 
24R,25(OH)2D3 (10-9,10-8, or 10-7M) (BioMol, Plymouth Meeting, PA) or vehicle alone.  
After the treatment period, 1ml of conditioned media was collected and cell monolayers 
were harvested using 0.05M sodium hydroxide (NaOH).  Media and lysate samples were 
spiked with 1 pmol of 17:0 LPA (internal standard) prior to lipid extraction via the Bligh-
Dyer method (Bligh 1959).  LC ESI MS/MS analysis was conducted at the Georgia 
Institute of Technology Bioanalytical Mass Spectrometry Facility using a Shimadzu 
HPLC pump and a Q-TRAP 4000 (Applied Biosystems, Foster City, CA).  Reverse phase 
chromatography was performed using a Supelco C18 column with a flow rate of 
500µl/min and an injection volume of 10µl.  The isocratic buffers were 75:25 
methanol:water (v/v) and methanol each with 5mM TEAA.  Eluted samples were then 
analyzed on the QTRAP 4000 and LPA isoforms were compared to LPA standards 
supplied by Avanti Polar Lipids.  Peak areas of LPA isoforms were normalized to 17:0 
peaks to account for differences in lipid extraction efficiency. 
7.4 LPA Receptor, Bax, Bcl-2, and p53 Expression   
mRNA was harvested from resting zone chondrocytes using Trizol (Invitrogen, 
Carlsburg, CA) and reverse transcriptase polymerase chain reaction (RT-PCR) was used 
to identify the presence of the LPA receptors LPA1-5 and PPAR-γ.  The following 
sequence specific primers were used: LPA1 sense: 5’-GGTTCTCTACGCTCACATC-3’, 
LPA1 antisense 5’-GCAGTAGCAAGACCAATCC-3’, LPA2 sense: 5’-
CACCACCTCACAGCCATCC-3’, LPA 2 antisense: 5’-
AGACATCCACAGCACTCAGC-3’, LPA3 sense: 5’-CTACAACAGGAGCAACAC-3’, 
LPA3 antisense: 5’-CCAGCAGGTAGTAGAAGG-3’, LPA4 sense: 5’-
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ACAACTTTAACCGCCACTGG-3’, LPA4 antisense: 5’-ATTCCTCCTGGTC 
CTGATGG-3’, LPA5 sense: 5’-ACCTTGGTGTTCCCTATAATGC-3’, LPA5 antisense: 
5’-AGCCAGAGCGTTGAGAGG-3’, PPAR-γ sense: 5’-
CCGAAGAACCATCCGATTGAAG-3’, and PPAR-γ antisense: 5’-
CTCCGCCAACAGCTTCTCC-3’.  In order to determine the effect of LPA on p53, Bax, 
and Bcl-2 mRNA expression, cells were treated with 0, 0.01, 0.1, and 1µM LPA for 6 h 
prior to harvesting the mRNA with Trizol.  The following primers were used to amplify 
p53, Bax, and Bcl-2: p53 sense: 5’-CCGTCCCAGAAGGTTGCC-3’, p53 antisense: 5’-
CGC TGC TCC GAA GGT GAT-3’, Bax sense: 5’-TTTGTTACAGGGTTTCATCC-3’, 
Bax antisense: 5’-CCAGTTCATCTCCAATTCG-3’, Bcl-2 sense: 5’-
CTCGTGGCTGTCTCTGAAG-3’, Bcl-2 antisense: 5’-TCTGCTGACCTCACTTGTG-
3’.  Glyceraldehyde-3-phosphate dehydrogenase (GADPH) was amplified as a control in 
each experiment: GAPDH sense: 5'-ATGCAGGGATGATGTTC-3', GAPDH antisense: 
5'-TGCACCA CCAACTGCTTAG-3'. 
7.5 Chondrocyte Maturation Assays   
Confluent cultures were treated with LPA (0.01nM to 1µM) for the times 
indicated below.  To determine if the LPA1/3 receptor was involved, cultures were also 
treated with LPA in the presence or absence of the LPA1/3-selective agonist (2S)-1-
oleoyl-2-O-methyl-glycero-3-phosphothionate (OMPT) (Avanti Lipids, Alabaster, AL) 
(0.1nM to 1µM) (Hasegawa, Erickson et al. 2003) or the LPA1/3-selective antagonist 
(S)-phosphoric acid mono-(2-octadec-9-enoylamino-3-[4-(pyridine-2-ylmethoxy)-
phenyl]-propyl) ester (VPC32183(S)) (Avanti Lipids) (0.01µM to 1µM) (Chang, Kim et 
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al. 2007).  Chondrocyte maturation was assessed by examining alkaline phosphatase 
specific activity and [35S]-sulfate incorporation.   
 To determine that 24R,25(OH)2D3 elicited its effects via an LPA-dependent 
mechanism, confluent cultures of resting zone cells were cultured for 24 hours in the 
presence and absence of the LPA1/3 selective antagonist VPC32183(S).  Alkaline 
phosphatase specific activity was measured as described below. 
Alkaline Phosphatase Specific Activity:  Initial experiments determined the optimal time 
course by treating confluent cultures with 1µM LPA for 3, 6, 12, 18, and 24 hours.  
Subsequent experiments were performed after treating the cells for 24 hours.  Following 
treatment, cell monolayers were lysed using 0.1% Triton X followed by sonication of 
each sample for 30 seconds.  Alkaline phosphate activity was measured in cell layer 
lysates as a function of release of para-nitrophenol from para-nitrophenylphosphate at 
pH 10.2.  Activity was normalized to the protein concentration of the lysates, determined 
using the macro-BCA assay (Macro BCA, Pierce Chemical Co., Rockford, IL). 
[35S]-Sulfate Incorporation: Mature chondrocytes produce a proteoglycan-rich 
extracellular matrix that is characterized by sulfated glycosaminoglycans.  To assess the 
effects of LPA on chondrocyte maturation, confluent cells were labeled with [35S]-sulfate 
3 hours prior to harvest.  At harvest, the conditioned media were removed, the cell layers 
(cells and matrix) were collected, and the amount of [35S]-sulfate incorporated was 
determined as a function of protein in the cell layer (Martin, Schwartz et al. 1995).   
7.6 DNA Synthesis  
To determine if LPA regulated chondrocyte proliferation, DNA synthesis was 
assessed by measuring the incorporation of radio-labeled thymidine.  Cells were grown to 
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sub confluence and treated with DMEM containing 1% FBS for 48 hours to induce 
quiescence.  Cells were then treated with LPA (0.1nM to 1µM) in the presence or 
absence of OMPT (0.1nM to 1µM) or VPC32183(S) (0.01µM to 1µM) for 24 hours.  
Prior to harvest, cells were labeled for 3 hours with [3H]-thymidine.  The monolayers 
were washed three times with phosphate buffer solution (PBS) to remove unincorporated 
[3H].  Cells were then fixed with cold 5% trichloroacetic acid followed by lysis with 1% 
sodium dodecyl sulfate.  The amount of [3H] activity was determined in each sample to 
determine the total amount of incorporated radio-labeled thymidine. 
7.7 Apoptosis Assays 
The role of LPA in chondrocyte survival was assessed by examining its ability to 
reduce apoptosis induced by two apoptogens: inorganic phosphate and chelerythrine 
(Teixeira, Mansfield et al. 2001; Zhong, Carney et al. 2008).  Apoptotic cell death was 
determined by measuring caspase-3 activity, TUNEL staining, and DNA fragmentation.  
Confluent cultures of resting zone chondrocytes were treated with either 10-5M 
chelerythrine or 7.5mM monobasic sodium phosphate to induce apoptosis.  LPA 
(0.01µM, 0.1 µM, or 1 µM), VPC32183(S) (0.01µM, 0.1 µM, or 1 µM), or the vehicle 
was added to the cultures.   
Caspase-3 Activity:  Caspase-3 activity was determined using the Colorimetric 
CaspACE™ Assay System from Promega (Madison, WI).  Cells were harvested 24h post 
treatment with 200µl cell lysis buffer followed by two 10 s periods of sonication.  After 
harvest, 2µl of the caspase-3 selective substrate DEVD-pNA were added to each well 
containing 100µl of cell lysate and incubated at 370C for 4h.  DEVD-pNA cleavage into 
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the colorimetric product pNA was measured at 405nm.  Caspase-3 activity was 
normalized to protein content as determined by the Pierce Macro BCA Protein Assay Kit.   
DNA Fragmentation:  Cells were labeled with [3H]-thymidine for 4 h prior to treatment.  
At the end of the treatment period, cell monolayers were washed with DMEM three times 
to remove unincorporated [3H] and cells were lysed with TE buffer (10mM Tris-HCl, 
1mM EDTA, 0.2% Triton X-100) for 30 minutes.  Cell lysates were centrifuged at 
13,000g for 15 minutes to separate intact DNA from fragmented DNA.  The amount of 
incorporated [3H]-thymidine was determined in each fraction to establish the total amount 
of fragmented DNA.   
TUNEL Staining:  DNA nicking was measured using the In Situ Cell Death Detection Kit 
(Roche Applied Science, Indianapolis, IN).  After treatment, cells were fixed using 4% 
paraformaldehyde in PBS for 1hour.  To detect nicks, cells were incubated with horse 
radish peroxidase-conjugated dUTP for 1hour at 370C.  Nicks were visualized with DAB 
substrate (3,3-diaminobenzidinetetrahydrochloride) also purchased from Roche. 
7.8 Regulation of p53 
Confluent cultures in T75 flasks were treated for 6 h with 0, 0.01, 0.1, and 1µM 
LPA.  After treatment, the cell monolayer was washed twice with PBS and harvested 
with RIPA buffer.  mRNA for p53 was determined as described above.  The abundance 
of p53 protein in both the whole cell lysate and nuclear and cytoplasmic fractions was 
determined by ELISA (p53 pan ELISA, Roche) and normalized to total cellular or total 
fraction protein as determined by Pierce Macro BCA Protein Assay Kit.  Nuclear and 
cytoplasmic fractions were isolated by centrifuging whole cell lysates for 10 minutes at 
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13,000 rpm.  The resulting supernatants (cytoplasmic fraction) were collected and the 
pellets (nuclear fraction) were resuspended in 500µL RIPA buffer. 
 To assess changes in p53-mediated transcription, luciferase reporter gene assays 
were conducted as previously described (Murph, Scaccia et al. 2003).  Cells were 
transfected with two plasmids: one containing p53-controlled firefly luciferase 
(pp53_TA-Luc, Clonetech, Mountain View, CA) and the other carrying constitutively 
expressed Renilla luciferase (pLR-TK, Promega, Madison, WI).  24 h after transfection, 
cells were treated with 0, 0.01, 0.1, and 1µM LPA for 16 h and luciferase activity was 
measured using the Dual Luciferase Reporter Assay kit (Promega, Madison, WI). 
7.9 Abundance of Bax, Bcl-2, and p21 Protein  
Western blots were performed to determine the effect of LPA on the protein 
abundance of Bax, Bcl-2, and p21.  Cell culture lysates were prepared from confluent 
resting zone cells and were resolved on 10% SDS-polyacrylamide gels.  Blots of the gels 
were probed with monoclonal antibodies against Bax (Δ 21, Santa Cruz Biotechnology, 
Inc.), Bcl-2 (DC 21, Santa Cruz Biotechnology, Inc.), p21 (BD Pharmingen, San Jose, 
CA), or GAPDH (MAB374 Chemicon, Billerica, MA).  Immunoreactive bands were 
detected using 1:5,000 dilutions of horseradish peroxidase-conjugated goat anti-rabbit 
IgG or goat anti-mouse IgG (Jackson Immunoresearch, West Grove, PA), and visualized 
using enhanced chemiluminescence (Super-Signal WestPico Chemiluminescent Substrate 





7.10 Statistical Analysis  
Each experiment had six independent cultures per variable to ensure sufficient 
power to detect statistically significant differences.  All experiments were conducted 
multiple times to validate the observations, but data from a single representative 
experiment are shown in the figures and are expressed as means + SEM.  Statistical 
analysis was conducted using ANOVA analysis followed by Student’s T-test with a 
Bonferroni modification.  Differences in means were considered to be statistically 




8.1 Resting Zone Chondrocytes Produce LPA and Express LPA Receptors 
 LC ESI MS/MS showed that three LPA isoforms, 16:0 LPA, 18:1 LPA, and 18:0 
LPA, were present in both the cell monolayer (Fig. 8.1A) and conditioned media (Fig. 
5.1B), indicating the existence of both intracellular and extracellular LPA in cultures of 
RC cells.  24R,25(OH)2D3 increased the abundance of 16:0 and 18:1 LPA in the media, 
but not in the cell monolayer.  The effect of 24R,25(OH)2D3 on both LPA forms was 
dose-dependent and was greatest in cultures treated with 10-8 M.  RT-PCR using 
sequence-specific primers detected the presence of the five cell surface G-protein coupled 
receptors, LPA1-5, and the nuclear receptor PPAR-gamma (Fig. 8.1C).  Distinct bands 
for LPA1, LPA3, and LPA4 were observed.  Bands for LPA2 and LPA5 were present but 
to a lesser extent.   
 24R,25(OH)2D3 exerted its effects on chondrocyte maturation via an LPA1/3 
dependent mechanism.  The LPA1/3-selective antagonist VPC32183(S) attenuated 
24R,25(OH)2D3-mediated increases in alkaline phosphatase activity (Fig. 8.1D). 
8.2 Exogenous LPA Enhances Chondrocyte Maturation 
 Initial time course experiments showed that LPA increased alkaline phosphatase 
specific activity at 24 hours, but no LPA effect was observed prior to this time point (data 
not shown).  For this reason, all future maturation experiments were conducted following 
a 24 hour exposure to the lipid mediator.  Both LPA and the LPA1/3-selective agonist 
OMPT increased alkaline phosphatase activity in the resting zone chondrocytes in a dose  
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FIGURE 8.1. Resting zone chondrocytes produce LPA and express LPA receptors.  
LPA isoform abundance was determined by LC ESI MS/MS from cell layer lysates (A) 
and media (B) collected from resting zone chondrocytes treated with media containing 
vehicle alone or 10-9 to 10-7 M 24R,25(OH)2D3.  (C) Total RNA was isolated from 
confluent cultures of male rat resting zone chondrocytes using Trizol.  LPA receptor 
cDNA was generated using specific reverse primers for LPA1-5, PPAR-γ, and GADPH 
and Omniscript Reverse Transcriptase (Qiagen).  LPA receptor fragments were amplified 
via polymerase chain reaction using sequence specific primers. (D) Male rat resting zone 
chondrocytes were treated with complete media or 24R,25(OH)2D3 in the presence or 
absence of the LPA1/3 selective antagonist VPC3218(S) for 24 h.  Alkaline phosphatase 
specific activity was measured in cell layer lysates as a function of release of para-
nitrophenol from para-nitrophenylphosphate at pH 10.2. (* =significant relative to 




dependent manner at concentrations ranging from 0.01µM to 1µM (Fig. 8.2A and 8.2C).  
The same concentrations of LPA and OMPT also increased [35S]-sulfate incorporation 
(Fig. 8.2B and 8.2D).  Furthermore, VPC32183(S) attenuated LPA-mediated increases in 
both alkaline phosphatase activity and [35S]-sulfate incorporation in a dose dependent 
manner (Fig 8.2E and 8.2F), indicating that the effects of LPA stimulation are dependent 
upon activation of LPA1 and/or LPA3.   
8.3 LPA Increases DNA Synthesis in a Dose-Dependent Manner   
Treatment of pre-confluent cells culture with 1µM LPA or OMPT enhanced DNA 
synthesis 100% over control cultures (Fig. 8.3A and 8.3B).  Inhibition of LPA1 and 
LPA3 with VPC321283(S) inhibited LPA-mediated increases in proliferation (Fig. 8.3C).  
These data demonstrate LPA promotes proliferation in resting zone chondrocytes through 
activation of LPA1 and/or LPA3. 
8.4 LPA Reduces the Stimulatory Effects of Phosphate and Chelerythrine Apoptosis 
 Both phosphate and chelerythrine increased DNA fragmentation relative to the 
control in a dose-dependent manner (Fig. 8.4A and 8.4B).  LPA doses ranging from 
0.01µM to 1µM completely and partially rescued phosphate and chelerythrine-induced 
DNA fragmentation, respectively.  Similarly, LPA reduced DNA nicking induced by both 
apoptogens, evidenced by reduced TUNEL staining (Fig 8.4C).  Inorganic phosphate and 
chelerythrine also increased caspase-3 activity and LPA reduced this marker of apoptosis 
as well (Fig. 8.4D, 8.4E).  The rescue of Pi-induced caspase-3 activity by LPA was 




FIGURE 8.2. LPA increases maturation in resting zone chondrocytes.  Chondrocyte 
maturation was determined by measuring alkaline phosphatase specific activity (A, C, E) 
and [35S]-incorporation (B, D, F).  Male rat resting zone chondrocytes were treated with 
complete media or varying concentrations of LPA (A, B) or the LPA1/3 selective agonist 
OMPT (C,D) for 24 h prior to harvesting the cell monolayer.  (E, F) Additionally, cells 
were treated with complete media or 1µM LPA in the presence or absence of the LPA1/3 
selective antagonist VPC3218(S) for 24 h.  Alkaline phosphatase specific activity was 
measured in cell layer lysates as a function of release of para-nitrophenol from para-
nitrophenylphosphate at pH 10.2.  In order to measure sulfate incorporation, cells were 
labeled with [35S]-sulfate 4 h prior to harvest.  At harvest, the conditioned media was 
removed, the cell layers (cells and matrix) were collected, and the amount of [35S]-sulfate 
incorporated determined as a function of protein in the cell layer. (* =significant relative 





FIGURE 8.3. LPA enhances proliferation.  DNA synthesis was determined by 
measuring the incorporation of radio-labeled thymidine.  Cells were grown to sub 
confluence and treated with DMEM containing 1% FBS for 48 hours to induce 
quiescence.  Male rat resting zone chondrocytes were treated with complete media or 
varying concentrations of LPA (A) or the LPA1/3 selective agonist OMPT (B) for 24 h 
prior to harvesting the cell monolayer.  Cells were alternatively treated with complete 
media or 1µM LPA in the presence or absence of the LPA1/3 selective antagonist 
VPC3218(S) for 24 h (C).  Prior to harvest, cells were labeled for 3 h with [3H]-
thymidine. The monolayers were washed three times with PBS to remove unincorporated 
[3H]. Cells were then fixed with cold 5% trichloroacetic acid followed by lysis with 1% 
sodium dodecyl sulfate. The amount of [3H] activity was determined in each sample to 
determine the total amount of incorporated labeled thymidine.  (* =significant relative to 










FIGURE 8.4. LPA protects cells from phosphate and chelerythrine-induced 
apoptosis. DNA fragmentation: Resting zone chondrocytes were labeled with [3H]-
thymidine for 4 h prior to treatment with the PKC inhibitor chelerythrine (A) or  7.5mM 
monobasic sodium phosphate (B) in the presence and absence of LPA for 24 h.  At the 
end of the treatment period, cell monolayers were washed with DMEM three times to 
remove unincorporated [3H] and cell were lysed with TE buffer (10mM Tris-HCL, 1mM 
EDTA, 0.2% Triton X-100) for 30 minutes.  Cell lysates were centrifuged at 13,000g for 
15 minutes to separate intact DNA from fragmented DNA.  The amount of incorporated 
[3H]-thymidine was determined in each fraction to establish the total amount of 
fragmented DNA.  TUNEL:  (C) Resting zone chondrocytes were treated with complete 
media (control), chelerythrine or 7.5mM monobasic sodium phosphate in the presence 
and absence of LPA for 24 h.  Cells were fixed using 4% paraformaldehyde in PBS for 1 
h.  DNA nicking was assessed using the In situ Cell Death Detection Kit (Roche) 
followed by analysis with light microscopy.  All images were obtained using an exposure 
time of 1.5 seconds.  Caspase-3 activity:  Caspase-3 activity was measured using the 
Colorimetric CaspACE™ Assay System (Promega) (D, E, F).  Resting zone 
chondrocytes were harvested after treatment with complete media (control), chelerythrine 
or 7.5mM monobasic sodium phosphate in the presence and absence of LPA and/or 
VPC32183(S) for 24 h.  Cell lysates were incubated with the caspase-3 substrate DEVD-
pNA.  Cleavage of DEVD-pNA into pNA was measured at 405nm and normalized to 
total protein. (* =significant relative to untreated control, • = significant relative to 







8.5 LPA Promotes Cell Survival via p53 Signaling 
 Control cultures of resting zone chondrocytes expressed p53 mRNA (Fig. 8.5A) 
and protein (Fig. 8.5B).  Treatment with LPA had no effect on p53 mRNA at 6 hours, but 
there was a decrease in p53 protein at this time point.  Nuclear p53 protein was decreased 
by LPA, whereas, cytoplasmic p53 did not change in response to the treatment (Fig 
8.5C).  Both p53-mediated transcription (Fig. 8.5D) and the abundance of the p53-target 
gene p21 (data not shown) were decreased by LPA.  Moreover, LPA decreased both the 
mRNA expression (Fig. 8.6A) and protein abundance (Fig. 8.6B) of Bax.  Conversely, 




FIGURE 8.5. LPA reduces p53 at the translational level but not at the 
transcriptional level.  RNA from resting zone chondrocyte cultures treated with 0, 0.01, 
0.1, or 1µM LPA for 6 h was collected using Trizol (A).  p53 and GAPDH cDNA were 
generated using specific reverse primers and Omniscript Reverse Transcriptase (Qiagen).  
Gene fragments were then amplified via polymerase chain reaction using sequence 
specific primers. Resting zone chondrocyte cultures were treated with complete media or 
with LPA for 6 hours prior harvest.  The abundance of p53 was measured in both the 
whole cell lysate (B) and the nuclear and cytoplasmic fractions (C) by p53 pan ELISA 
(Roche).  p53-mediated transcription was assessed as a function of normalized luciferase 
activity (D).  Cells were transfected with p53-controlled firefly luciferase and 
constitutively active Renilla luciferase.  24 h post-transfection, cells were treated with 










FIGURE 8.6. Bax and Bcl-2 mRNA and protein abundance are regulated by LPA.  
(A) Total RNA was isolated from male rat resting zone chondrocyte cultures using 
Trizol.  Bax, Bcl-2, and GAPDH cDNA was generated using specific reverse primers and 
Omniscript Reverse Transcriptase (Qiagen).  Gene fragments were amplified via 
polymerase chain reaction using sequence specific primers.  (B) Resting zone 
chondrocyte cultures were treated with complete media or with LPA for 6 hours prior to 
immunoblotting of whole-cell extracts with mouse anti-Bcl-2, mouse anti-Bax, or mouse 





Our results indicate that LPA is an autocrine regulator in the growth plate resting 
zone (Fig 9.1).  Resting zone chondrocytes contain intracellular LPA and secrete 
extracellular LPA.  The LPA isoforms identified, 16:0, 18:1, and 18:0, are the most 
biologically relevant of the LPA isoforms (Sando and Chertihin 1996; Pustilnik, Estrella 
et al. 1999; Sugiura, Nakane et al. 2002). In addition, LPA receptors are present in RC 
cells, demonstrating that they have the potential to respond to this phospholipid 
metabolite.  Moreover, 24R,25(OH)2D3 increased the extracellular abundance of LPA 
16:0 and LPA 18:1 and the LPA1/3-selective antagonist VPC32183(S) attenuated 
24R,25(OH)2D3-mediated maturation, suggesting that LPA may act as a downstream 
mediator of vitamin D metabolite effects on resting zone cells.   
This study demonstrates that LPA signaling plays a role in the maintenance of the 
resting zone cartilage by promoting the survival of the chondrocyte pool.  At least two 
mechanisms are involved in the inhibition of apoptosis.  LPA acts via reduced p53 and its 
downstream mediator p21, reduced Bax and increased Bcl-2.  This is particularly 
important because resting zone cells serve as the pool for the growth zone and premature 
cell death in the resting zone could result in premature closure of the growth plate and 
limb shortening.  In addition, LPA stimulated DNA synthesis, suggesting that LPA is 
involved in maintaining the pool of resting zone chondrocytes via proliferation.  LPA has 
been shown to act as a mitogen in other systems (van Corven, Groenink et al. 1989; 
Sautin, Crawford et al. 2001; Kue, Taub et al. 2002; Radeff-Huang, Seasholtz et al. 2004; 








FIGURE 9.1. Proposed mechanism of LPA signaling in the resting zone of the 
growth plate.  24R,25(OH)2D3-mediated stimulation of phospholipase D (PLD) 
promotes the conversion of phosphatidyl choline (PC) to phosphatidic acid (PA) leading 
to LPA production.  LPA stimulates LPA1 and/or LPA3, resulting in increases alkaline 
phosphatase activity, [35S]-incorporation, and proliferation.  LPA also decreases the 
abundance and transcriptional activity of the tumor suppressor p53 causing an increase in 











2005).  However, it decreased proliferation of T/C-28a2 cells, a human articular 
chondrocyte-like cell line (Facchini, Borzi et al. 2005), raising the possibility that its 
effects are cell specific.   
In addition to its stimulatory effects on DNA synthesis, LPA increased [35S]-
sulfate incorporation, suggesting an increase in the synthesis of a sulfated proteoglycan 
extracellular matrix around the newly generated chondrocytes.  Alkaline phosphatase 
specific activity also increased, supporting the hypothesis that the chondrocytes were 
producing a mature matrix containing alkaline phosphatase-rich extracellular matrix 
vesicles (Boyan, Schwartz et al. 1990).  
Our results strongly support a physiological role for LPA in promoting 
chondrocyte survival in the resting zone.  We demonstrated by four different methods 
(DNA fragmentation, TUNEL staining, caspase-3 activity, and Bcl-2/Bax ratio) that LPA 
signaling reduced the induction of apoptosis by two agents shown previously to stimulate 
the apoptotic pathway in resting zone chondrocytes in vitro (Teixeira, Mansfield et al. 
2001; Zhong, Carney et al. 2008).  Moreover, the ability of LPA to rescue the apoptotic 
effect of Pi was attenuated by the LPA1/3 receptor antagonist, indicating that LPA1/3 
signaling was responsible.  The timing of programmed cell death is crucial in the 
maintenance of the growth plate.  Inhibition of apoptotic signaling in hypertrophic 
chondrocytes prevents their terminal differentiation (Pucci, Adams et al. 2007), resulting 
in lengthening of the growth plate as is typically seen in the vitamin D-deficient rickets.  
Phosphate plays an important role in this process (Mansfield, Pucci et al. 2003), but it 
isn’t known if the phosphate content is also a regulator of apoptosis in the resting zone.   
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Cell proliferation is associated with an increase in protein kinase C (PKC) in 
many cell types (Nishizuka 1984; Sylvia, Mackey et al. 1994), and LPA reduced the 
effects of PKC inhibition by chelerythrine.  Previously we have showed that 
24R,25(OH)2D3 stimulates PKC and cell proliferation in resting zone chondrocytes via a 
PLD-dependent mechanism (Schwartz, Sylvia et al. 2001). Our results suggest that LPA 
may mediate this response.   
The LPA-induced decrease in the cellular abundance of the tumor suppressor p53 
may be involved as well.  The reduction of p53 correlates enhanced cell survival (Bartek, 
Iggo et al. 1990), indicating that the inhibition of p53 is the mechanism of LPA-mediated 
protection against cell death.  The inhibition of p53 has also been implicated in the 
maturation of osteoblasts (Lengner, Steinman et al. 2006; Tataria, Quarto et al. 2006), 
suggesting that LPA-mediated decreases in p53 may be significant in chondrocyte 
maturation in addition to enhancing survival in these cells.  LPA altered p53-mediated 
transcription and the expression of the p53-target genes p21, Bax and Bcl-2 at the 
transcriptional and translational level.  The change in the cellular Bax to Bcl-2 ratio 
would result in the inhibition of the release of cytochrome c from the mitochondria 
(Jurgensmeier, Xie et al. 1998), halting the initiation of the apoptotic proteolytic caspase 
cascade.  This is supported by our finding that LPA inhibits chelerythrine and phosphate-
induced caspase-3 activity via an LPA1/3 mediated mechanism.  Collectively, our results 
define a pathway for LPA-mediated enhancement of cell survival and chondrocyte 
maturation by which LPA decreases the abundance of p53 to alter p53-target gene 
expression resulting in the inhibition of caspase activity. 
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 In summary, LPA was found to be a stimulator of resting zone chondrocyte 
proliferation and maturation and an inhibitor of chondrocyte apoptosis.  This confirms a 
physiological role for LPA as a regulator of growth plate cartilage, and suggests that LPA 
produced via 24R,25(OH)2D3-stimulated PLD activity may mediate the actions of the 
seco-steroid in growth plate resting zone chondrocytes.  Additionally, this establishes 
LPA as a potential therapeutic regulatory agent in controlling the processes of 













PART III. 24R,25-DIHDROXYVITAMIN D3 PROTECTS 
CHONDROCYTES FROM APOPTOSIS THROUGH MODULATION 





Longitudinal bone growth in children and adolescents is mediated by growth plate 
cartilage, which is divided into four zones of maturation: the resting zone, the growth 
zone, the pre-hypertrophic/hypertrophic zone, and the calcifying cell zone.  Inorganic 
phosphate (Pi), a physiological apoptogen, induces apoptosis in terminal growth plate 
chondrocytes at the epiphyseal-metaphyseal junction (Teixeira, Mansfield et al. 2001; 
Mansfield, Pucci et al. 2003; Zhong, Carney et al. 2008), allowing for the invasion of 
blood vessels and deposition of new bone.  The resting zone of the growth plate supplies 
a pool of chondrocytes for the remainder of the growth plate.  In response to growth 
stimuli, these cells undergo proliferation, terminal differentiation, hypertrophy, and 
apoptosis as they mature.  Resting zone chondrocytes response preferentially to the 
vitamin D metabolite 24R,25-dihydroxyvitamin D3 [24R,25(OH)2D3], resulting in 
increased matrix production, maturation, and cell survival (Sylvia, Schwartz et al. 1997; 
Boyan, Sylvia et al. 2001; Dean, Boyan et al. 2001; Schwartz, Ehland et al. 2002).  
24R,25(OH)2D3  exerts its effects through a membrane-associated vitamin D receptor 
(Boyan, Sylvia et al. 2003) resulting in activation of phospholipase D (PLD) and 
production of lysophosphatidic acid (LPA 18:1; 1-oleoyl-2-hydroxy-sn-glycero-3-
phosphate), a bioactive lysophospholipid that regulates bone and cartilage (Sylvia, 
Schwartz et al. 2001; Hurst-Kennedy, Boyan et al. 2009). 
LPA is the most simple of the glycerol lipids consisting of a single fatty acyl 
chain, a glycerol backbone, and a phosphate head group.  LPA exerts its effects on cell 
through activation of the cell surface G-protein coupled receptors (GPCRs) LPA1/Edg2, 
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LPA2/Edg4, LPA3/Edg7, LPA4/GPR23, and LPA5/GPR92 and through the nuclear 
receptor peroxisome-proliferation-activation-receptor gamma (PPARγ) (Chun 1999; 
Goetzl and An 1999; McIntyre, Pontsler et al. 2003; Noguchi, Ishii et al. 2003; Lee, 
Rivera et al. 2006).  Consequences of LPA signaling are broad and include neurite 
retraction, tumorigenesis, wound healing, proliferation, migration, and cell survival (van 
Corven, Groenink et al. 1989; Xu, Shen et al. 1998; Deng, Balazs et al. 2002; Fang, 
Schummer et al. 2002; Mills and Moolenaar 2003; Hama, Aoki et al. 2004; Ren, Xiao et 
al. 2006). Several recent studies have demonstrated that chondrocytes, osteoblasts, and 
osteocytes are sensitive to LPA, establishing LPA as a regulator of bone and cartilage 
(Facchini, Borzi et al. 2005; Kim, Lee et al. 2005; Karagiosis and Karin 2007; 
Panupinthu, Zhao et al. 2007; Panupinthu, Rogers et al. 2008).  
Recently, we observed that 24R,25(OH)2D3 protects the resting zone 
chondrocyte-like ATDC5 cell line from Pi-induced apoptosis (Denison, Koch et al. 
2009).  Additionally, our group has reported that LPA is produced by resting zone 
chondrocytes in response to 24R,25(OH)2D3 and that the lipid mediator acts as an 
autocrine regulator to promote proliferation, cell survival, and maturation (Hurst-
Kennedy, Boyan et al. 2009).  LPA exerts these effects through activation of LPA1 
and/or LPA3 and by modulating the abundance and transcriptional activity of the tumor 
suppressor p53.  In cancer cells, LPA has been shown to regulate p53 in a similar manner 
through activation of the phosphoinositol 3-kinase (PI3K) signaling cascade to promote 
nuclear export and subsequent degradation of p53 (Murph, Hurst-Kennedy et al. 2007).  
Collectively, these findings have led us to hypothesize that 24R,25(OH)2D3 protects 
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resting zone chondrocytes from Pi-induced apoptosis through LPA-mediated inhibition of 
p53. 
 Our goal was to elucidate the mechanisms by which 24R,25(OH)2D3 and LPA 
promote cell survival in the resting zone of the growth plate in the presence of Pi.  We 
found that 24R,25(OH)2D3-mediated inhibition of Pi-induced apoptosis is dependent 
upon Gαi, PLD, phosphatidylinositol-dependent phospholipase C (PI-PLC), and Ca
++-
dependent signaling and through the inhibition of p53.  Gαi, PI3K, nuclear export, and 
mdm2 signaling are necessary for the attenuation of Pi-induced cell death by LPA.  
Moreover, 24R,25(OH)2D3 attenuates Pi-induced cytochrome c translocation.  Therefore, 
we have determined that 24R,25(OH)2D3 protects resting zone chondrocytes from Pi-
induced apoptosis by producing LPA, which subsequently activates LPA1/3.  This results 
in Gαi-mediated stimulation of PI3K signaling leading to mdm-2-directed degradation of 
p53.  Additionally, we found that 24R,25(OH)2D3 promotes Gαi-associated Gβγ signaling 
to induce PI-PLC-mediated calcium release from the endoplasmic reticulum.  
Collectively, these pathways act to enhance cell survival in the resting zone in the 
presence of Pi. 
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CHAPTER 11 
MATERIALS AND METHODS 
11.1 Reagents   
18:1 LPA (1-oleoyl-2-hydroxy-sn-glycero-3-phosphate) was purchased from 
Avanti Polar Lipids (Alabaster, AL) and was reconstituted in 1% charcoal-stripped 
bovine serum albumin (BSA) prior to treatment of cells.  Unless otherwise stated, all 
other reagents were acquired from VWR International (West Chester, PA).  
11.2 Cell Culture   
The culture system used in this study has been previously described in detail 
(Boyan, Schwartz et al. 1988).  Chondrocytes were obtained from the resting zone 
(reserve zone) of costochondral cartilage from 125-g male Sprague-Dawley rats and 
cultured in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal bovine 
serum (FBS), 1% antibiotics, and 50µg/ml ascorbic acid (GIBCO-BRL, Gaithersburg, 
MD).  Primary cells were cultured until fourth passage prior to experimental analysis. 
11.3 Regulation of LPA Receptor Expression   
Confluent cultures of resting zone chondrocytes were treated for 6 hrs with 
vehicle alone (control), 7.5mM sodium phosphate, 1e-6M LPA, or 1e-7M 
24R,25(OH)2D3.  After treatment, mRNA was harvested using Trizol (Invitrogen, 
Carlsburg, CA).  Quantitative real-time polymerase chain reaction (QRT-PCR) was used 
to identify the presence of the LPA receptors LPA1-5 and PPAR-γ.  The following 
sequence specific primers were used: LPA1 sense: 5’-GGTTCTCTACGCTCACATC-3’, 
LPA1 antisense 5’-GCAGTAGCAAGACCAATCC-3’, LPA2 sense: 5’-
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CACCACCTCACAGCCATCC-3’, LPA 2 antisense: 5’-
AGACATCCACAGCACTCAGC-3’, LPA3 sense: 5’-CTACAACAGGAGCAACAC-3’, 
LPA3 antisense: 5’-CCAGCAGGTAGTAGAAGG-3’, LPA4 sense: 5’-
ACAACTTTAACCGCCACTGG-3’, LPA4 antisense: 5’-ATTCCTCCTGGTC 
CTGATGG-3’, LPA5 sense: 5’-ACCTTGGTGTTCCCTATAATGC-3’, LPA5 antisense: 
5’-AGCCAGAGCGTTGAGAGG-3’, PPAR-γ sense: 5’-
CCGAAGAACCATCCGATTGAAG-3’, and PPAR-γ antisense: 5’-
CTCCGCCAACAGCTTCTCC-3’.  Glyceraldehyde-3-phosphate dehydrogenase 
(GADPH) was amplified as a control in each experiment: GAPDH sense: 5'-
ATGCAGGGATGATGTTC-3', GAPDH antisense: 5'-TGCACCA CCAACTGCTTAG-
3'. 
11.4 Cell Viability    
We used the LPA1/3-selective antagonist (S)-phosphoric acid mono-(2-octadec-9-
enoylamino-3-[4-(pyridine-2-ylmethoxy)-phenyl]-propyl) ester (VPC32183(S), Avanti 
Polar Lipids, Alabaster, AL) (Chang, Kim et al. 2007) to assess the role of LPA receptor 
signaling in 24R,25(OH)2D3-mediated rescue of Pi-induced apoptosis.  Confluent 
cultures of the resting zone chondrocytes were treated with 7.5mM monobasic sodium 
phosphate, 10-7M 24R,25(OH)2D3, VPC32183(S) (0.01µM-1µM), or a combination of 
the aforementioned.  Cell viability was assessed using the MTT (3-[4,5-dimethylthiazol-
2yl]-2,5-diphenyltetrazolium bromide, Sigma, St. Louis, MO) dye.  The conversion of 
tetrazolium salt to formazan salt was measured at 570nm.  
11.5 Caspase-3 Activity   
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The roles of 24R,25(OH)2D3 and LPA in chondrocyte survival were assessed by 
examining its ability to reduce caspase-3 activity induced by inorganic phosphate 
(Teixeira, Mansfield et al. 2001; Zhong, Carney et al. 2008).  Confluent cultures of 
resting zone chondrocytes were treated for 24h with 7.5mM monobasic sodium 
phosphate (Pi) to induce apoptosis. At the same time, cells were treated with 
24R,25(OH)2D3 (1e-7M) or LPA (1e-6M).  VPC32183(S) was used to inhibit LPA1/3 
signaling (1e-8M – 1e-6M, Avanti Polar Lipids, Alabaster, AL); pertussis toxin was used 
to inhibit Gαi signaling (PTX, 25ng/ml-0.25ng/ml, Sigma, St. Louis, MO).  Cholera toxin 
was used to stimulate Gαs signaling (CTX, 100ng/ml-1ng/ml, Calbiochem, Gibbstown, 
NJ), while LY294002 was used to inhibit PI3K activity (LY, 10µM-0.1µM, Cayman 
Chemicals, Ann Arbor, MI). D609 (50µM, Calbiochem, Gibbstown, NJ) and U73122 
(10µM, Sigma, St. Louis, MO) were used to inhibit phosphatidylcholine-specific PLC 
(PC-PLC) and PI-PLC, respectively.  Thapsigargin was used to block release of calcium 
from the endoplasmic reticulum (3µM, Sigma, St. Louis, MO).  Wortmannin was used to 
inhibit PLD and PI3K signaling (10µM, Calbiochem, Gibbstown, NJ); leptomycin B was 
used to block nuclear export (LMB, 50ng/ml-0.5ng/ml, Biomol, Plymouth Meeting, PA).  
Caspase-3 activity was determined using the colorimetric CaspACE™ Assay System 
from Promega (Madison, WI).  Cells were harvested 24h post treatment with 200µl cell 
lysis buffer followed by two 10 s periods of sonication.  After harvest, 2µl of the caspase-
3 selective substrate DEVD-pNA were added to each well containing 100µl of cell lysate 
and incubated at 370C for 4h.  DEVD-pNA cleavage into the colorimetric product pNA 
was measured at 405nm.  Caspase-3 activity was normalized to protein content as 
determined by the Pierce Macro BCA Protein Assay Kit.   
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11.6 Modulation of p53 Abundance and p53-Mediated Transcription   
Confluent cultures of resting zone chondrocytes were treated for 6 h with 0, 10-
9M, 10-8M, 10-7M 24R,25(OH)2D3.  After treatment, the cell monolayer was washed 
twice with PBS and harvested with RIPA buffer. The abundance of p53 protein in both 
the whole cell lysate and nuclear and cytoplasmic fractions was determined by ELISA 
(p53 pan ELISA, Roche) and normalized to total cellular or total fraction protein as 
determined by Pierce Macro BCA Protein Assay Kit.   
To assess changes in p53-mediated transcription, luciferase reporter gene assays 
were conducted as previously described (Murph, Scaccia et al. 2003).  Cells were 
transfected with two plasmids: one containing p53-controlled firefly luciferase 
(pp53_TA-Luc, Clonetech, Mountain View, CA) and the other carrying constitutively 
expressed Renilla luciferase (pLR-TK, Promega, Madison, WI).  24 h after transfection, 
cells were treated with 0, 10-9M, 10-8M, 10-7M 24R,25(OH)2D3 for 16 h and luciferase 
activity was measured using the Dual Luciferase Reporter Assay kit (Promega, Madison, 
WI). 
11.7 Abundance of mdm2 and Phospho-mdm2 Protein   
Western blots were performed to determine the effects of 24R,25(OH)2D3 and 
LPA on the protein abundance of mdm2 and phosphorylated mdm2.  Cell culture lysates 
were prepared from confluent resting zone cells and were resolved on 10% SDS-
polyacrylamide gels.  Blots of the gels were probed with monoclonal antibodies against 
mdm2 (AbCam, Cambridge, MA), Phospho-mdm2 (Ser 166, Cell Signaling, Boston, 
MA), or GAPDH (MAB374 Chemicon, Billerica, MA).  Immunoreactive bands were 
detected using 1:5,000 dilutions of horseradish peroxidase-conjugated goat anti-rabbit or 
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goat anti-mouse IgG (Jackson Immunoresearch, West Grove, PA), and visualized using 
enhanced chemiluminescence (Super-Signal WestPico Chemiluminescent Substrate 
(Pierce Biotechnology, Rockford, IL). Densitometry measurements were collected using 
Quantity One image analysis software (BioRad, Hercules, CA). 
11.8 Cytochrome C Translocation   
Confluent cultures of resting zone chondrocytes were mock-treated (control) or 
treated with 7.5mM Pi, 1e-7M 24R,25(OH)2D3, or a combination of the afore mentioned 
for 24 h.  At harvest, cell lysates were fractionated into mitochondrial and cytoplasmic 
fractions using the Cytochrome C Apoptosis Assay Kit (BioVision, Mountain View, CA).  
Immunoblotting was conducted as described previously using a mouse monoclonal anti-
cytochrome c antibody (BioVision). 
11.9 Statistical Analysis   
Each experiment had six independent cultures per variable to ensure sufficient 
power to detect statistically significant differences.  All experiments were conducted 
multiple times to validate the observations, but data from a single representative 
experiment are shown in the figures and are expressed as means + SEM.  Statistical 
analysis was conducted using ANOVA analysis followed by Student’s T-test with a 
Bonferroni modification.  Differences in means were considered to be statistically 




12.1 LPA Receptor Expression is Regulated by LPA, Phosphate, and 
24R,25(OH)2D3  
Resting zone chondrocytes express the LPA receptors LPA1-5 and peroxisome-
proliferation activation receptor gamma (PPAR-γ).  Both 1e-7M 24R,25(OH)2D3 and 1e-
6M LPA increased the mRNA expression of LPA1 (Fig 12.1A, 12.1B).  Expression of 
LPA3, LPA4, and LPA5 was decreased after treatment with 7.5mM phosphate (Fig 
12.1B). 
12.2 24R,25(OH)2D3 Inhibits Apoptosis Through LPA1/3 Signaling 
24R,25(OH)2D3 inhibited Pi-induced apoptosis as assessed by MTT cell viability 
assay (Fig. 12.2A) and caspase-3 activity assay (Fig. 12.2B).  The LPA1/3-selective 
antagonist VPC32183(S) abolished the ability of 24R,25(OH)2D3 to reduce the increase 
in caspase-3 activity caused by Pi. 
12.3 24R,25(OH)2D3 and LPA Inhibit Phosphate-Induced Caspase-3 Activity 
 24R,25(OH)2D3 reduced Pi-induced caspase-3 activity (Fig. 12.3).  The Gαi 
inhibitor pertussis toxin (PTX) (Fig. 12.3A) attenuated 24R,25(OH)2D3-mediated rescue, 
whereas the Gαs stimulator cholera toxin (CTX) (Fig. 12.3B), the PI3K inhibitor 
LY294002 (Fig. 12.3C), and the PC-PLC inhibitor D609 (Fig. 12.3D) did not.  The PI-
PLC inhibitor U73122, calcium ATPase inhibitor thapsigargin, and the PLD/PI3K 












FIGURE 12.1. LPA receptor expression is regulated by LPA, phosphate, and 
24R,25(OH)2D3.  RNA was isolated via Trizol extraction from cultures of resting zone 
chondrocytes the were mock-treated (Control C,D) or treated with 1e-7M 
24R,25(OH)2D3, 7.5mM Pi, or 1e-6M LPA.  LPA receptor mRNA abundance was 












FIGURE 12.2 24R,25(OH)2D3 inhibits apoptosis through LPA1/3 signaling. 
Confluent cultures of resting zone chondrocytes were treated with 1e-7M 
24R,25(OH)2D3, 7.5mM Pi, VPC32183(S) (1e-8, 1e-7, 1e-6M), or a combination of the 
aforementioned for 24 hours.  After the treatment period, cell viability was assessed by 








FIGURE 12.3. 24R,25(OH)2D3 inhibits Pi-induced caspase-3 activity through Gαi, 
PLD, and Ca++-dependent signaling. Confluent cultures of resting zone chondrocytes 
were treated for 24h with 7.5mM monobasic sodium phosphate, 24R,25(OH)2D3 (10-7M), 
pertussis toxin (A, PTX, 25ng/ml-0.25ng/ml), cholera toxin (B, CTX, 100ng/ml-1ng/ml), 
LY294002 (C, 10µM-0.1µM), D609 (D, 50µM), U73122 (E, 10µM), thapsigargin (F, 
3µM), Wortmannin (G, 10µM) or a combination of the aforementioned. Caspase-3 
activity was determined using the Colorimetric CaspACE™ Assay System from Promega 








 LPA treatment also attenuated the increase in caspase-3 activity induced by Pi 
(Fig 12.4).  This rescue of Pi-induced apoptosis by LPA was inhibited by PTX, but not by 
CTX (Fig. 12.4A, 12.4B).  LY294002 and the nuclear export inhibitor leptomycin B 
(LMB) also blocked LPA-mediated inhibition of Pi cell death (Fig. 12.4C, 12.4D).  
12.4 24R,25(OH)2D3 Modulates p53 Levels and Activity 
24R,25(OH)2D3 treatment resulted in a decrease in p53 abundance (Fig. 12.5A) 
and p53-mediated transcription (Fig. 12.5B) as assessed by ELISA and luciferase reporter 
gene assay, respectively.  24R,25(OH)2D3 did not alter the abundance of active, 
phosphorylated or total mdm2, an E3 ubiquitin ligase that negatively regulates p53 (Fig. 
12.6A).  LPA, however, did increase the phosphorylation mdm2 (Fig. 12.6B).   
12.5 Pi-Induced Cytochrome C Translocation is Attenuated by 24R,25(OH)2D3 
 Cytochrome c is primarily localized in the mitochondria in control and 
24R,25(OH)2D3 treated lysates (Data not shown, Ming Zhong).  Pi treatment induced an 
increase in the abundance of cytochrome c in the cytoplasmic fraction, while decreasing 










FIGURE 12.4. LPA inhibits Pi-induced caspase-3 activity through Gαi, PI3K, and 
nuclear export-dependent signaling.  Confluent cultures of resting zone chondrocytes 
were treated for 24h with 7.5mM monobasic sodium phosphate, LPA (1 µM), pertussis 
toxin (3A, PTX, 25ng/ml-0.25ng/ml), cholera toxin (3B, CTX, 100ng/ml-1ng/ml), 
LY294002 (3C, 10µM-0.1µM), leptomycin B (3D, LMB, 50ng/ml-0.5ng/ml), or a 
combination of the aforementioned. Caspase-3 activity was determined using the 
Colorimetric CaspACE™ Assay System from Promega and normalized to total protein. 




FIGURE 12. 5. 24R,25(OH)2D3 reduces p53 abundance and p53-mediated 
transcription.  (A) Resting zone chondrocytes were treated with 0, 1e-7M, 1e-8M, or 1e-
9M 24R,25(OH)2D3. The abundance of p53 protein in both the nuclear and cytoplasmic 
fractions was determined by ELISA (p53 pan ELISA, Roche) and normalized to total 
fraction protein. (B) Cells were transfected with two plasmids: one containing p53-
controlled firefly luciferase and the other carrying constitutively expressed Renilla 
luciferase.  After 24 h, cells were treated with 0, 1e-7M, 1e-8M, or 1e-9M 
24R,25(OH)2D3 for 16 h and luciferase activity was measured using the Dual Luciferase 
Reporter Assay kit (Promega). Firefly luciferase activity was normalized to Renilla 
luciferase activity to determine p53-mediated transcription. 
 
 
Figure 4.  24R,25(OH)2D3 decreases p53 abun an e and p53-mediated transcription. 
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FIGURE 12.6. LPA and 24R,25(OH)2D3 regulate mdm2 phosphorylation 
differently. Confluent cultures of resting zone chondrocytes were treated with 
24R,25(OH)2D3 (A, 0, 1e-9, 1e-8, or 1e-7M) or LPA (B, 0, 1e-8, 1e-7, or 1e-6M) for 6 






Our data demonstrate that 24R,25(OH)2D3 inhibits Pi-induced apoptosis in resting 
zone chondrocytes through LPA signaling.  Previously, we have shown that 
24R,25(OH)2D3 increases the abundance of extracellular LPA and that 24R,25(OH)2D3-
stimulated alkaline phosphatase activity is dependent upon LPA1/3 receptor signaling 
(Hurst-Kennedy, Boyan et al. 2009).  In this study, we demonstrate that 24R,25(OH)2D3 
also increases the expression of LPA1 mRNA and that 24R,25(OH)2D3-mediated 
inhibition of Pi-induced apoptosis is sensitive to the LPA1/3-selective antagonist 
VPC32183(S).  Collectively, these observations implicate LPA as a second messenger 
during the promotion of cell maturation and survival in chondrocytes by 24R,25(OH)2D3.  
Recently, a single nucleotide polymorphism (SNP) in LPA1 has been indentified in 
osteoarthritic patients (Mototani, Iida et al. 2008).  Moreover, the LPA1-/- mouse exhibits 
a smaller skeleton relative to wild-type mice (Contos, Ishii et al. 2002).  These findings, 
in conjunction with our own demonstrating that 24R,25(OH)2D3 and LPA (Hurst-
Kennedy, Boyan et al. 2009) exert their effects in chondrocytes via LPA1 and/or LPA3, 
indicate that LPA1 is significant in the regulation of cartilage.  
We have found that LPA-mediated rescue of Pi-induced apoptosis is sensitive to 
pertussis toxin and LY294002, but not to cholera toxin.  This indicates that LPA exerts its 
anti-apoptotic effects through Gαi and PI3K signaling.  A consequence of activation of 
this cascade is the activation of Akt/protein kinase B (PKB) (Downward 2004).  Akt 
phosphorylates mdm2 inducing its translocation into the nucleus where it mono- and 
poly-ubiquitinates p53 (Li, Brooks et al. 2003; Milne, Kampanis et al. 2004).  This results 
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in the nuclear export and subsequent proteosomal degradation of p53.  Our data show that 
the reduction of caspase-3 by LPA is sensitive to the nuclear export inhibitor leptomycin 
B and that LPA increases the phosphorylation of mdm2, supporting the claim that LPA is 
modulating p53 through this pathway.  Interestingly, this is the mechanism by which 
LPA inhibits p53 signaling in A549 lung carcinoma cells (Murph, Hurst-Kennedy et al. 
2007), suggesting that this pathway is conserved amongst different cell types. 
In our study, 24R,25(OH)2D3-mediated inhibition of Pi-induced caspase-3 activity 
was not inhibited by the PI3K inhibitor LY294002.  Moreover, 24R,25(OH)2D3 did not 
increase the abundance of phosphorylated mdm2 at 6hr post-treatment.  This suggests 
that 24R,25(OH)2D3 is stimulating one or more additional pathways to inhibit apoptosis 
in addition to LPA-mediated inhibition of p53.  Resting zone chondrocytes mature in 
response to 24R,25(OH)2D3 through increased PKC and PKA activity, resulting in 
MEK1/2 signaling (Schwartz, Ehland et al. 2002).  It is possible that activation of these 
effectors also enhances cell survival.  Another possible pathway is the PLC signaling 
cascade. 24R,25(OH)2D3-mediated inhibition of apoptosis was attenuated by pertussis 
toxin, a Gαi inhibitor.  Pertussis toxin also inhibits Gαi-associated Gβγ signaling, which 
can stimulate PLC activation (Smrcka and Sternweis 1993; Smrcka 2008).  Our data 
show that LPA1/3, PI-PLC, and release of intracellular calcium from the endoplasmic 
reticulum are necessary for the inhibition of apoptosis by 24R,25(OH)2D3.  Taken 
together, this suggests that 24R,25(OH)2D3 is initiating LPA-mediated stimulation of 
Gβγ-induced PLC activity, resulting in release of intracellular calcium.  
Resting zone chondrocytes responds to 24R,25(OH)2D3 with increased 
proliferation, maturation, and matrix production (Helm, Sylvia et al. 1996; Sylvia, 
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Schwartz et al. 1997).  In this study we demonstrate that 24R,25(OH)2D3 also protects 
chondrocytes from apoptosis induced by Pi in their microenvironment.  Together, this 
suggests that 24R,25(OH)2D3 stabilizes chondrocytes in the resting zone by inhibiting 
degradation characteristic of apoptotic hypertrophic chondrocytes.  This implies that 
24R,25(OH)2D3 modulates growth plate development by controlling the rate and extent 
of chondrocyte transition from resting zone to growth zone phenotype. 
In summary, our data identify a new signaling axis in the inhibition of apoptosis 
in the growth plate (Fig. 13.1).  Chondrocytes respond to 24R,25(OH)2D3, which 
stimulates the signaling of its second messenger, LPA, resulting in inhibition of p53 
signaling and enhanced cell survival.  Information gleaned from this study provides new 
understanding into the maintenance of the pool of chondrocytes in the resting zone of the 
growth plate.  Therefore, we identify this signaling axis as a potential therapeutic target 
for the treatment of bone fracture repair and as a regulatory agent of endochondral 





FIGURE 13.1. Mechanisms of 24R,25(OH)2D3 and LPA-mediated inhibition of 
apoptosis in resting zone chondrocytes.  Resting zone chondrocytes respond to 
24R,25(OH)2D3, resulting in increased phospholipase D (PLD) activity.  Activation of 
PLD stimulates the production of lysophosphatidic acid (LPA).  Stimulation of LPA1/3 
receptor(s) by LPA leads to activation of Gαi and phoshoinositol-3 kinase (PI3K) 
signaling.  This results in increased phosphorylation of the E3-ubiquitin ligase murine 
double minute 2 (mdm2).  Phospho-mdm2 translocates to the nucleus where it can mono- 
or poly-ubiquitinate p53 to promote its nuclear export and proteosomal degradation.  A 
decrease in p53 protein abundance and nuclear localization yields reduced p53-mediated 
transcription and decreased caspase-3 activity, resulting in increased cell survival, 
maturation, and proliferation. 24R,25(OH)2D3 also stimulates PKC and PKA signaling 
and modulates intracellular calcium levels through Gβγ-mediated PLC activation, which 





CONCLUSIONS AND FUTURE DIRECTIONS 
14.1 Summary  
The overall goal of this study was to determine the mechanism by which LPA 
regulates cell death.  In the first study, we found that LPA enhances resistance to 
chemotherapy-induced apoptosis in A549 lung carcinoma cells by stimulating the 
degradation of the tumor suppressor p53.  This results in decreased p53-mediated 
transcription and enhanced cell survival.  In the second study, we found that LPA-
directed regulation of cell death has a physiologically relevant role in the maintenance of 
the growth plate.  The vitamin D metabolite 24R,25(OH)2D3 stimulates PLD-mediated 
LPA production resulting in increased proliferation, maturation, and inhibition of 
apoptosis.  LPA exerts many of these effects through modulation of p53 signaling.  In the 
final study, we investigated the mechanisms behind the inhibition of cell death by 
24R,25(OH)2D3 and LPA in the growth plate.  We found that LPA is a second messenger 
in 24R,25(OH)2D3-mediated inhibition of apoptosis.  Consequences of LPA signaling 
include Gαi, PI3K, mdm2-induced degradation of p53. Gαi-associated Gβγ signaling also 
plays a role by initiating PLC-directed calcium release from the endoplasmic reticulum. 
The 24R,25(OH)2D3, LPA, p53 signaling axis has the potential to affect human 
health in both negative and positive manners.  On the one hand, the inhibition of p53 by 
LPA has the capacity to promote tumorigenesis.  Conversely, stimulating 24R,25(OH)2D3 
and/or LPA signaling may be effective in improving bone fracture healing and in treating 
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endochondral ossification-related disorders.  The applications of this work will be 
discussed as followed. 
14.2 Modulation of LPA Signaling in the Treatment of Cancer 
Our data show that LPA enhances the resistance of A549 lung carcinoma cells to 
the chemotherapeutic drug actinomycin D.  This suggests that LPA signaling in vivo may 
help cancer cells evade apoptosis, especially in breast, prostate, and ovarian cancers 
where LPA signaling is known to enhance tumorigenesis.  Therefore, administrating 
inhibitors of LPA signaling in conjunction with chemotherapeutics may improve 
chemotherapeutic-induced tumor cell death.  The inhibitors could include LPA receptor 
antagonists to decrease LPA-mediated signaling or inhibitors of enzymes that generate 
LPA such as ATX or AGK.   
Since LPA regulates a wide array of cellular functions, it is important to consider 
systemic effects resulting from modulation of LPA signaling.  A general decrease in LPA 
signaling could result in reduced blood clotting and inflammatory responses, impairing 
the body’s ability to heal.  Recently, a group has found that administration of proteasome 
inhibitor to children with cancer causes irreversible growth retardation (Zaman, 
Menendez-Benito et al. 2007).  This phenomenon is attributed to increased levels of p53 
in growth plate chondrocytes.  Given our data demonstrating the importance of LPA-
mediated inhibition of p53 in growth plate maintenance, inhibition of LPA signaling in 
children with cancer may also cause growth retardation.  Therefore, delivery vehicles that 
administer drugs locally should be considered while developing LPA inhibitors as anti-
cancer therapeutic agents. 
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The vitamin D metabolite 1,25(OH)2D3 is an established inhibitor of tumor 
formation in skin (Chida, Hashiba et al. 1985; Pence, Richard et al. 1991).  Recently, an 
inverse relationship has been identified between breast cancer occurrence and sunlight 
exposure, suggesting a role for this metabolite in other types of cancer (Millen, Pettinger 
et al. 2009).  Moreover, 1,25(OH)2D3 is an inducer of p53 and the downstream p53 target 
BRCA1 (Campbell, Gombart et al. 2000; Gupta, Dixon et al. 2007).  Together, these data 
implicate 1,25(OH)2D3 as an anti-tumor agent.  Our findings, however, suggest that the 
metabolite 24R,25(OH)2D3 may promote tumorigenesis by stimulating LPA-mediated 
inhibition of p53.  Therefore, it may be interesting to examine the levels of 1,25(OH)2D3 
and 24R,25(OH)2D3 in the tumor microenvironment as cancer progresses.  It may be that 
tumors enrich their environment preferentially with 24R,25(OH)2D3 in order to evade 
chemotherapeutic-induced cell death.  Consequently, including inhibitors of 24-
hydrolyase and/or 1,25(OH)2D3  analogues in an anti-cancer drug regiment may inhibit 
tumor progression.  
14.3 LPA as a Regulator of Fracture Repair and Skeletal Development and Growth 
Disruptions in embryonic growth plates severely impair or abolish skeletal 
formation.  Moreover, premature closure of post-natal growth plates halts long bone 
growth, resulting in shorter stature.  Our findings demonstrate that resting zone growth 
plate chondrocytes respond to LPA with increased proliferation, maturation, and cell 
survival.  Additionally, 24R,25(OH)2D3 increases both LPA1 receptor expression and 
extracellular LPA abundance, resulting in decreased Pi-induced apoptosis.  Collectively, 
these observations strongly suggest that LPA is significant in maintaining the pool of 
chondrocytes in the resting zone of the growth plate and subsequently is important during 
 104 
endochondral ossification.  Consequently, these findings make LPA an attractant 
therapeutic target for controlling skeletal development and growth. 
Due to the structural and biological similarities between growth plates and 
fracture calluses, our data also suggest that LPA may enhance bone fracture healing.  
Others have found that LPA signaling promotes osteoblast-mediated mineralization and 
osteocyte reconnectivity (Gidley, Openshaw et al. 2006; Karagiosis and Karin 2007; 
Panupinthu, Rogers et al. 2008), implicating LPA in the later stages of fracture healing. 
Based on our results, it is possible that LPA signaling also enhances the viability of 
chondrocytes in the fracture callus during the intermediate stage of healing.  Collectively, 
this work suggests that administration of LPA at a fracture site after injury could enhance 
the healing process.  In vivo animal studies examining the role of LPA in fracture repair 
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